Document:

EX-10.18

 Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

Exhibit 10.18 
 LICENSE AGREEMENT 
 This License Agreement, effective on the 28th day of
July, 2011 (the “Effective Date”), is entered into by and between Celldex Therapeutics, Inc., a Delaware corporation having a principal place of business at 119 Fourth Avenue, Needham, MA 02494 (hereinafter
“Celldex”) and Argos Therapeutics, Inc., a Delaware corporation having a principal place of business at 4233 Technology Drive, Durham, NC 27704 (“Argos”). Celldex and Argos are sometimes referred to herein
individually as a “Party” and collectively as the “Parties”. 
 WHEREAS, Celldex is the owner
of certain patents rights (as further defined below, the “Licensed Patents”); and 
 WHEREAS, Argos desires to
practice certain inventions claimed in the Licensed Patents, under the terms and conditions set forth herein. 
 NOW, THEREFORE,
in consideration of the above premises and the mutual covenants contained herein, the Parties agree as follows. 
 1. DEFINITIONS.
The terms in this Agreement with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth below or, if not listed below, the meaning designated in places throughout this Agreement. 

“Affiliate” shall mean any corporation or other entity which controls, is controlled by, or is under common control with a Party. A
corporation or other entity shall be regarded as in control of another corporation or entity if it owns or directly or indirectly controls more than fifty percent (50%) of the voting stock or other ownership interest of the other corporation or
entity, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or other entity or the power to elect or appoint more than fifty percent (50%) of the members of
the governing body of the corporation or other entity. 
 “Field” means the diagnosis, prevention or treatment of [**] and such
other diseases, disorders or indications, if any, as may be added pursuant to Section 2.2. 
 “Licensed Patents” means US
Patents [**] and any other U.S. patents (including divisionals, continuations, continuations-in-part, etc.) assigned to Celldex as of the Effective Date or during the
term of this Agreement that are derived from or claim priority to any of the foregoing or from US Patent Application Ser. No. [**] or US Patent Application Ser. No. [**] in each case together with non-US
counterparts of any of the foregoing that claim priority to any of the foregoing, specifically including those set forth on Exhibit A. 

“Process” means any process employed in the production of Product the practice of which, absent a grant of the license set forth herein,
would constitute infringement of a Valid Claim in any of the Licensed Patents. [**]. 
 “Product” means [**] alone or in
combination with one or more agent, in each case the manufacture or sale of which, absent a grant of the license set forth herein, would constitute infringement of a Valid Claim in any of the Licensed Patents. 

“Third Party” means any entity other than Celldex or Argos and their respective Affiliates. 

“Valid Claim” means a claim of an issued and unexpired patent that has not been held permanently revoked, unenforceable or invalid by a
decision of a court or other governmental 

  
 1 

 
agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal. 
 2. LICENSE RIGHTS AND OPTION GRANT; PATENT MAINTENANCE 
 2.1. License.
Subject to the terms and conditions of this Agreement, Celldex hereby grants to Argos a royalty-bearing, non-exclusive license under the Licensed Patents to perform Processes and to develop, make, have made,
sell, have sold, use and import Product in the Field. 
 2.2. Option to Expand License Field. Upon payment of [**] US dollars (US$[**])
per new indication, Argos may add additional oncology or infectious disease indications to the Field. 
 2.3. Outsourcing and
Sublicensing. Argos may authorize a Third Party contract manufacturer to perform Processes and/or produce Product for sale by or on behalf of Argos or its Affiliates, without Celldex’s consent or any obligation of Argos to make payment.
Argos may authorize a Third Party (other than a contract manufacturer) to perform Processes and/or produce Product in connection with the grant of rights to manufacture Product pursuant to a licensing or similar transaction, in which case Argos
shall, within [**] days of the grant of such sublicense, pay Celldex [**] US dollars (US$[**]). Any other sublicense of rights to practice under the Licensed Patents requires the consent of Celldex, not to be unreasonably withheld or delayed.

 2.4. No Other Licenses. No right or license is granted hereunder except as expressly set forth herein. 

2.5. Patent Maintenance. Celldex shall prosecute and maintain the Licensed Patents at its expense and in its sole discretion and shall have the
right but no obligation to maintain any of the Licensed Patents. Celldex shall, from time to time (no less than [**] or upon Argos’ reasonable request, such requests not exceeding [**] per year) provide Argos with copies of any patents issued
in respect of the Licensed Patents and with written notice of the abandonment, termination or cancellation of any patent rights in respect of the Licensed Patents. Argos agrees to cooperate fully with Celldex in securing any available patent term
extensions or Supplementary Protection Certificates (SPCs) in respect of the Licensed Patents in Celldex’s name. Upon Celldex’s reasonable request, Argos shall promptly provide copies of any regulatory marketing authorizations, product
licenses and supporting development information as may be necessary or helpful in the pursuit of such patent term extensions or SPCs. Celldex shall use such information solely for the purposes set forth in this paragraph and shall otherwise treat
such information as Argos’s Confidential Information. Nothing herein shall be deemed to limit the ability of Argos to seek patent term extensions or SPCs with respect to any other patent rights owned, licensed or otherwise controlled by Argos.

 3. PAYMENTS. 
 3.1.
Upfront and Annual License Fee. In consideration of the license granted hereunder, Argos shall pay to Celldex an upfront license fee of one hundred thousand US dollars (US$100,000.00). payable fifty percent (50%) within three
(3) business days after execution of this Agreement and fifty percent (50%) upon the earlier of (a) the initiation (i.e., administration of the first dose to a human subject) of the next clinical trial of Product sponsored by Argos in
the Field, or (b) January 31, 2012 (“Upfront License Fee”). Additionally, in order to maintain the license granted hereunder, Argos shall pay Celldex an annual license fee of seventy-five thousand US dollars (US$75,000.00)
on each anniversary of the Effective Date, until the first commercial sale of a Product (“Annual Fee”). 

  
 2 

 3.2. Milestone. Upon the first commercial sale of a Product during the Term, Argos will pay Celldex a
milestone payment of [**] US dollars (US$[**]), less the amount of the Upfront License Fee and Annual Fees already paid to Celldex. 
 3.3.
Royalties. Within [**] days after the end of each calendar year during the Term commencing with the calendar year which includes the first commercial sale of a Product, Argos will pay to Celldex a royalty payment of [**] US dollars ($[**])
per dose of Product sold by Argos, its Affiliates or sublicensees during that year subject to an annual maximum royalty amount of [**] US dollars (US$[**]). 
 3.4. Manner of Payment. Payments to be made by Argos to Celldex under this Agreement shall be payable in United States dollars and shall be paid by bank wire transfer in immediately available funds
to such account as Celldex may designate by written notice. 
 4. REPRESENTATIONS AND WARRANTIES; DISCLAIMER; LIABILITY.

 4.1. Representations and Warranties. 
 4.1.1. Celldex represents and warrants to Argos that (a) it is the assignee of the Licensed Patents and has all requisite power and authority to enter into this Agreement and to grant the licenses
granted by it hereunder, (b) execution of this Agreement has been duly authorized, (c) this Agreement is fully binding and enforceable in accordance with its terms, (d) Celldex’s execution and performance under this Agreement
does not conflict with any other agreement, contracts or other arrangements related to the Licensed Patents to which Celldex is party, and (e) the Licensed Patents listed on Exhibit A constitute all of the Licensed Patents issued or
applied for which remain in force to Celldex’s knowledge as of the Effective Date. 
 4.1.2. Argos represents and warrants
to Celldex that: (a) it has all requisite power and authority to enter into this Agreement and to perform its obligations under this Agreement, (b) execution of this Agreement has been duly authorized, (c) this Agreement is fully
binding and enforceable in accordance with its terms, and (d) Argos’s execution and performance under this Agreement does not conflict with any other agreement, contracts or other arrangements to which Argos is party. 

4.2. WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, CELLDEX MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND,
EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE LICENSED PATENTS RIGHTS OR ANY LICENSE GRANTED BY CELLDEX HEREUNDER, OR WITH RESPECT TO ANY PRODUCTS OR
SERVICES OF ARGOS. FURTHERMORE, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE LICENSED PATENTS ARE VALID OR ENFORCEABLE OR THAT ARGOS’ ACTIVITIES RELATED TO ITS RIGHTS
GRANTED PURSUANT TO THIS AGREEMENT OR CONTEMPLATED HEREUNDER WILL NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 

  
 3 

 4.3. Liability, Indemnification. Argos shall bear all risk and responsibility and liability for all
of its activities in exercising its rights under this Agreement and shall indemnify and hold Celldex and its Affiliates and their respective directors, officers and employees harmless against any and all claims, demands, losses, costs, expenses
(including attorney fees), damages and judgments related to its activities in exercising its rights under this Agreement including but not limited to: product liability; any claim for death, bodily injury or property damage arising from the
research, development, manufacture, use, distribution, sale or commercialization of any Product or Process by Argos, its Affiliates, sublicensees, employees or agents; Argos’s breach of the Agreement and/or Argos’s or any of its
Affiliates’, agents’, manufacturers’ or sublicensees’ negligence or willful misconduct. 
 5. REPORTING &
AUDITING. 
 5.1. Record Keeping. For the duration of the Term of this Agreement plus [**] years, Argos agrees that it
will keep accurate and complete records, relevant to: 
  

	 	(a)	The first commercial sale of the Product; and 

  

	 	(b)	the number of doses of Product sold. 

 5.2.
Yearly Reporting. Argos shall provide Celldex with detailed product development and royalty reports within [**] days after the end of each calendar year. 
 5.3. First Commercial Sale. Argos shall report to Celldex the first commercial sale of Product promptly upon its occurrence. 
 5.4. Audit. At any time during the term of this Agreement and for a period of [**] years thereafter, Celldex may, upon not less than [**] days advance written notice, have the records of Argos
reviewed and examined by an auditor reasonably acceptable to Argos. If any examination requested by Celldex pursuant to this Section reveals an underreporting or underpayment of five percent (5%) or more, Argos shall bear the full cost of such
audit and shall remit any amounts due to Celldex within [**] days of receiving such notice of amounts due. 
 6. ASSIGNMENT.

 6.1. Non Assignment by Argos. Except as set forth in Section 6.3, this Agreement is not assignable by Argos to any person other
than an Affiliate without Celldex’s prior written consent, which shall not be unreasonably withheld.  
 6.2. Assignment by
Celldex. Celldex may at any time, without Argos’ consent, assign its rights and obligations hereunder in connection with the transfer of the Licensed Patents, provided that such assignee or successor in interest agrees in writing to be
bound by the terms of this Agreement. 
 6.3. Change in Control of Argos. Argos may transfer the license granted hereunder in connection
with a merger, change in control or the sale or other disposition of all or substantially all of its rights to Product; provided, however, that Argos is required to pay Celldex a fee of [**] US dollars (US$[**]) upon the first occurrence of such an
event during the Term. The fee payable under this Section shall be payable one (1) time only. For clarification, a bona fide financing shall not be deemed to constitute a change in control. 

7. TERM AND TERMINATION. 

  
 4 

 7.1. Term. This Agreement, unless earlier terminated, shall remain in full force and effect on a country-by-country basis until the expiration of the last to expire of any Valid Claim included in the Licensed Patents in such country. 

7.2. Termination for breach. Upon any material breach of this Agreement by either Party (in such capacity, the “Breaching
Party”), the other Party may terminate this Agreement by providing [**] days written notice to the Breaching Party, specifying the material breach. The termination shall become effective at the end of the [**] day period unless:
(i) the Breaching Party cures such breach during such [**] day period, (ii) if such breach is not susceptible to cure within [**] days of the receipt of written notice of the breach, the Breaching Party is diligently pursuing a cure
(unless such breach, by its nature, is incurable, in which case the Agreement may be terminated immediately), or (iii) the Breaching Party has commenced dispute resolution pursuant to Section 8.2 (in which event, such termination shall not
be effective unless the arbitrator determines that the Party in breach has materially breached or defaulted in the performance of any of its material obligations hereunder); provided, however, in the case of a failure to pay any amount due
hereunder, such default may be the basis of termination [**] business days following the date that notice of such default was provided to the Breaching Party. If Argos or any of its its Affiliates or any manufacturer or sublicensee commences any
legal proceeding that challenges the validity, enforceability or ownership of any of the Licensed Patents, Celldex shall have the right to immediately terminate the license granted by Celldex pursuant to Section 2 under the challenged patent(s)
by giving written notice to Argos. 
 7.3. Termination by Argos At Will. Argos shall have the right to terminate this Agreement upon
written notice to Celldex. 
 7.4. Effect of Termination. Upon termination or expiration of this Agreement, for any reason, all rights
and licenses granted to Argos hereunder shall terminate. The termination of this Agreement shall not affect any rights or obligations of either Party that have accrued or matured prior to termination and which are intended by the Parties to survive
termination Without limiting the generality of the foregoing, early termination of this Agreement shall in no event remove Argos’ obligation to pay the full Upfront License Fee. For avoidance of doubt, the second fifty percent (50%) of the
Upfront License Fee shall remain payable in full by Argos under Section 3.1 of this Agreement upon the earlier of (a) the initiation (i.e., administration of the first dose to a human subject) of the next clinical trial of Product
sponsored by Argos in the Field, or (b) January 31, 2012 regardless of the date of any termination or expiration of this Agreement and regardless of whether or not any such termination or expiration may be before or after the earlier of
3.1(a) or 3.1(b). 
 7.5 Survival. The provisions of Sections 3, 4, 5, 7.4 and 8 of this Agreement, as well as any other Sections or
defined terms referred to in such Sections or necessary to give them effect shall survive termination or expiration of this Agreement and remain in force until discharged in full. Furthermore, any other provisions required to interpret and enforce
the parties’ rights and obligations or to wind up their outstanding obligations under this Agreement shall survive to the extent required. 
  

	8.	MISCELLANEOUS. 

 8.1 Recitals
and Headings. Recitals, headings and captions of the Articles and Sections hereof are for convenience only and are not to be used in the interpretation of this Agreement. 

  
 5 

 8.2. Applicable Law; Arbitration. The Parties agree that all disputes arising under this Agreement
shall be determined in accordance with the laws of the State of New York, without regard to conflict of laws principles which would dictate the application of the law of a different jurisdiction. 

8.3 Entire Agreement. This Agreement, including any exhibits or attachments hereto constitutes the complete and final understanding of Celldex and
Argos with respect to the subject matter hereof, and supersedes any and all oral and/or written communications or understandings relating to the subject matter hereof, provided however that the Parties remain obligated under any confidentialty or
nondisclosure agreement previously entered into between them. 
 8.4 Waivers and Modifications. The failure of any Party to insist on the
performance of any obligation hereunder shall not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision. No waiver,
modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by both Parties hereto. 
 8.5 Relationship of the Parties. It is expressly agreed that the relationship between Argos and Celldex shall not constitute a partnership, joint venture or agency. Neither Argos nor Celldex shall
have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other, without the prior consent of the other Party to do so. 

8.6 Counterparts. This Agreement may be executed in counterparts with the same effect as if both Parties had signed the same document. All such
counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. 
 8.7
Severability. In performing this Agreement, the Parties shall comply with all applicable laws. Wherever there is any conflict between any provision of this Agreement and any law, the law shall prevail, but in such event the affected provision
of this Agreement shall be limited or eliminated only to the extent necessary, and the remainder of this Agreement shall remain in full force and effect. In the event the terms of this Agreement are materially altered as a result of the foregoing,
the Parties shall renegotiate in good faith the terms of this Agreement to resolve any inequities. 
  

	8.8	Confidentiality. 

 (a) As used in this Agreement, the term “Confidential Information” means any technical or business information furnished by one Party (the “Disclosing Party”) to the other Party (the
“Receiving Party”) in connection with this Agreement and specifically designated as confidential. Such Confidential Information may include, without limitation, the trade secrets, know-how, inventions, formulations, compositions, technical
data or specifications, testing methods, business or financial information, research and development activities, product and marketing plans, and customer and supplier information. Confidential Information that is disclosed in writing shall be
marked with the legend “CONFIDENTIAL.” Confidential Information that is disclosed orally or visually shall be documented in a written notice prepared by the Disclosing Party and delivered to the Receiving Party within [**] days of the date
of disclosure. Such notice shall summarize the Confidential Information disclosed to the Receiving Party and reference the time and place of disclosure. 

  
 6 

 (b) The Receiving Party shall and shall cause its employees engaged in the
performance of this Agreement to: (i) maintain all Confidential Information in strict confidence, except that the Receiving Party may disclose or permit the disclosure of any Confidential Information to its directors, officers, employees,
consultants, and advisors who are obligated to maintain the confidential nature of such Confidential Information and who need to know such Confidential Information to perform this Agreement; (ii) use all Confidential Information solely for
purposes performing this Agreement; and (iii) reproduce the Confidential Information only to the extent necessary to perform this Agreement, with all such reproductions being considered Confidential Information. 

(c) The obligations of the Receiving Party under Section 6.1(b) shall not apply to Confidential Information to the
extent that the Receiving Party can demonstrate by competent evidence that such applicable Confidential Information: (i) was in the public domain prior to the time of its disclosure under this Agreement; (ii) entered the public domain
after the time of its disclosure under this Agreement through means other than an unauthorized disclosure resulting from an act or omission by the Receiving Party; (iii) was independently developed or discovered by the Receiving Party without
resort to such Confidential Information; (iv) is or was disclosed to the Receiving Party at any time, whether prior to or after the time of its disclosure under this Agreement, by a Third Party having no fiduciary relationship with the
Disclosing Party and having no obligation of confidentiality with respect to such Confidential Information; or (v) is required to be disclosed to comply with applicable laws or regulations, or with a court or administrative order, provided that
the Disclosing Party receives, to the extent practicable, prior written notice of such disclosure and that the Receiving Party takes all reasonable and lawful actions to obtain confidential treatment for such disclosure and, if possible, to minimize
the extent of such disclosure. 
 (d) Upon the termination by either Party of this Agreement, the Receiving Party
shall return to the Disclosing Party all originals, copies, and summaries of documents, materials, and other tangible manifestations of Confidential Information in the possession or control of the Receiving Party, except for one copy which may be
kept in the Receiving Party’s legal archives. The obligations set forth in this Section shall remain in effect for a period of [**] years after receipt of the Confidential Information by the Receiving Party. 

(e) Celldex and Argos each agree not to disclose any terms or conditions of this Agreement to any Third Party without the
prior consent of the other Party, except as required by law and for any disclosure in confidence to a Party’s accountants, counsel, financial advisors and existing and prospective sources of funding. If the filing of this Agreement with the
Securities and Exchange Commission or other applicable securities regulators is required, the parties agree to seek confidential treatment with respect to the filing of this Agreement to the extent possible. 

8.9 Notices. Any notice or other communication pursuant to this Agreement shall be sufficiently made or given on the date of mailing if sent to
such Party by facsimile on such date, with paper copy being sent by certified first class mail, postage prepaid, or by next day express delivery service, addressed to it at its address below (or such address as it shall designate by written notice
given to the other Party). 

  
 7 

			
	 If to Celldex:
  

Celldex Therapeutics, Inc.
  

222 Cameron Dr.
  

Phillipsburg, NJ 08865
  

Attn: President and CEO
  

cc: Chief Business Officer
	  	 If to Argos:
  

Argos Therapeutics, Inc.
  
 4233 Technology Drive
  
 Durham,
NC 27704
  
 Attn: Patent Department

 
 with a copy to:

 
 Hutchison Law Group
 5410 Trinity Road, Suite 400
 Raleigh, NC 27607

Attn: William N. Wofford

  
 8 

 IN WITNESS WHEREOF, the Parties hereto, intending to be legally bound, have executed this Agreement by their
duly authorized officers. 
  

									
	Celldex Therapeutics, Inc.	 		 	Argos Therapeutics, Inc.
					
	By:	 	/s/ Ronald A. Pepin	 		 	By:	 	/s/ Jeffrey D. Abbey
					
	Name:	 	Ronald A. Pepin, Ph.D.	 		 	Name:	 	Jeffrey D. Abbey
					
	Title:	 	SVP and Chief Business Officer	 		 	Title:	 	President & CEO

  
 9 

 Exhibit A 
 Licensed Patents 
 US Patents: 

 

					
	Patent No	  	Title	 	Issue date
	 [**]
	  	[**]	 	[**]
	 [**]
	  	[**]	 	[**]
	 [**]
	  	[**]	 	[**]
	 [**]
	  	[**]	 	[**]
	
[**]
	  	[**]	 	[**]

 Patents outside the US 
  

					
	Patent No	  	Title	 	Issue date
	 [**]
	  	[**]	 	[**]
	 [**]
	  	[**]	 	[**]
	
[**]
	  	[**]	 	[**]

  
 10EX-10.19

 Exhibit 10.19 
 Confidential Materials omitted and filed separately with the 
 Securities and
Exchange Commission. Double asterisks denote omissions. 
 LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (the “AGREEMENT”) made and entered into this tenth day of January, 2000, by and between DUKE UNIVERSITY,
a North Carolina not-for-profit corporation, (hereinafter called “DUKE”), having its principal office at Durham, North Carolina 27708, and MERIX BIOSCIENCE,
INC., a Delaware corporation organized under the laws of Delaware (hereinafter called “MERIX”), having a mailing address at P.O. Box 14509, Research Triangle Park, North Carolina 27709. 

WHEREAS, Eli Gilboa and Smita Nair are inventors of an invention [the “1101 INVENTION” hereinafter] described in Duke Office of
Science and Technology File #1101 and in related patent applications defined hereinafter; and 
 WHEREAS, Eli Gilboa, Smita
Nair, and David Boczkowski are inventors of an invention [the “1215 INVENTION” hereinafter] described in Duke Office of Science and Technology File #1215 and in related patent applications defined hereinafter; and 

WHEREAS, DUKE has the right to grant licenses to the 1101 INVENTION and to the 1215 INVENTION under PATENT RIGHTS (as hereinafter
defined), and wishes to have the inventions covered by the PATENT RIGHTS utilized in the public interest; and 
 WHEREAS, DUKE
represents that it is the sole owner of the entire right, title and interest in and to said inventions and PATENT RIGHTS; and 

WHEREAS, DUKE granted to Dendritix, Inc. in an Option Agreement made the eighteenth day of December 1998 an option to obtain an exclusive
license to the 1101 INVENTION and also to the 1215 INVENTION under the terms and conditions specified hereinafter; and 

WHEREAS, Dendritix, Inc. has changed its corporate name to Merix Bioscience, Inc.; and 

WHEREAS, MERIX has informed DUKE that it wishes to exercise its exclusive option to license the 1215 INVENTION and the 1101 INVENTION
under the terms and conditions specified hereinafter; and 
 WHEREAS, MERIX represents that it intends to develop and
commercialize the Patents Rights so that products made under the PATENT RIGHTS shall become available to the public; and 
 NOW
THEREFORE, in consideration of the premises and the faithful performance of the covenants herein contained, IT IS AGREED: 

ARTICLE 1 - DEFINITIONS 
 1.01 - For the purposes of this AGREEMENT, and solely for that purpose, the terms and phrases set forth hereinafter in capital letters shall be defined as follows: 

 

	 	a.	“FIELD” shall mean all uses of the know-how and patent rights, cell lines, substances and material produced by cell
lines and included in PATENT RIGHTS, specifically including, without limitation, research and development, diagnosis, prevention, therapy, and monitoring of all human and animal diseases or disorders. 

  
 - 1 -

	 	b.	“PATENT RIGHTS” shall mean all U.S. and foreign Patent Applications filed to protect the 1101 INVENTION or the 1215 INVENTION and any patent now issued or
hereafter issuing on any such patent application, substitutes, continuations, extensions, renewals, reissues, reexaminations, additions, continuations-in-part,
divisionals, or reissues thereof and any patent revalidations, registrations, supplementary protection certificates, patents of importation or cautionary notices thereof in connection with the 1101 INVENTION or 1215 INVENTION. As of the EFFECTIVE
DATE of this AGREEMENT, PATENT RIGHTS related to the 1101 INVENTION include [**]. As of the EFFECTIVE DATE of this AGREEMENT, PATENT RIGHTS related to the 1215 INVENTION include [**]. 

 

	 	c.	“Know-How” shall mean any research information, technical information, technical data or other confidential information not in the public domain made or that
may be made by one of the inventors of the 1101 INVENTION or the 1215 INVENTION and/or one of them and others working under the supervision of one of them, while students or employees of DUKE prior to or during the term of this AGREEMENT, which
relate to and are necessary for the practice of the PATENT RIGHTS in the FIELD. For avoidance of doubt, Know-How shall include all unpatented and unpatentable inventions, technology, cell lines, biological
materials, compounds, probes, sequences, and methods necessary for the practice of the PATENT RIGHTS under this AGREEMENT. Know-How shall not, however, include any such materials or information or any uses of
such materials and information that DUKE cannot provide to MERIX on either an exclusive or non-exclusive basis because of other legal obligations of DUKE pursuant to sponsored research, clinical research,
material transfer, confidentiality or other agreements. 

  

	 	d.	“VALID CLAIM” means a claim of an issued patent which has not lapsed or become abandoned or been declared invalid or unenforceable by a court of competent
jurisdiction or an administrative agency for which there is no right of appeal or for which the right of appeal is waived. 

  

	 	e.	“LICENSED PRODUCT” shall mean any product which is produced or sold by MERIX that utilizes the KNOW-HOW or that
infringes one or more VALID CLAIMS of the PATENT RIGHTS, and which is intended for use in, or is used in, the FIELD. 

  

	 	f.	“NET SALES” shall mean the total invoiced sales of LICENSED PRODUCTS sold by MERIX, less the following sums actually paid or credited by MERIX as shall be
detailed in MERIX’s reports made pursuant to Section 5.02 of this AGREEMENT: 

  

	 	(a)	trade, quantity or cash discounts or commissions allowed in amounts customary in the trade; 

  
 - 2 -

	 	(b)	any tax, excise or other governmental charge upon or measured by the production, sale, transportation, delivery or use and duties imposed on the import of LICENSED
PRODUCTS included in such amount; 

  

	 	(c)	outbound transportation charges prepaid or allowed on the cost of shipping to customers, if any; and 

 

	 	(d)	credits or allowances, if given or made for LICENSED PRODUCTS, price adjustments, returns, rejections, recalls or destructions (voluntarily made by or requested or made
by an appropriate government agency, subdivision or department) of LICENSED PRODUCTS previously delivered. 

LICENSED PRODUCTS used by MERIX for its own use in the FIELD, LICENSED PRODUCTS sold to Affiliates, and internal sales for use in service
businesses in arms length transactions shall be considered to be NET SALES for purposes of computing royalty obligations, except such LICENSED PRODUCT used for non-revenue producing activity such as
promotional items or field trials shall not be considered to be NET SALES. 
  

	 	g.	“AFFILIATE” shall mean any entity which controls, is controlled by or is under common control with MERIX. An entity shall be regarded as in control of another
entity if it owns or controls more than fifty percent (50%) of the voting power of the entity. 

  

	 	h.	“FOUNDERS” shall mean H. Kim Lyerly, Eli Gilboa, Clay Smith, and Bruce Sullenger, the scientific founders of MERIX, and “FOUNDER” shall mean any of
these individuals. 

  

	 	i.	“OPTIONED INVENTION” shall mean an invention having been made solely or jointly by a FOUNDER while the FOUNDER was employed by DUKE subsequent to the
EFFECTIVE DATE and during the term of this AGREEMENT in the field of autoimmune diseases or disorders, infectious diseases or cancer in humans or animals and useful for: (i) active and/or adoptive immunological intervention intended for therapy
or prevention; (ii) monitoring of immunological parameters for diagnosis, therapy or the development of candidate interventions; or (iii) discovery of new antigens for diagnosis, monitoring or therapy; provided, however, that such an
invention shall not be an OPTIONED INVENTION if DUKE is legally unable to grant MERIX an option for an exclusive license (or if an exclusive license is not legally possible, a non-exclusive license) to such
invention under the terms of sponsored research, clinical research, material transfer, confidentiality or other agreements with third parties; and provided furthermore that any invention related to stem cells shall not be an OPTIONED INVENTION.
Nothing in the foregoing definition of OPTIONED INVENTION shall be construed as limiting the right of FOUNDERS or DUKE to enter into sponsored research, clinical research, material transfer, confidentiality, or other agreements granting intellectual
property rights to any other party, not for profit or for profit, provided that such agreements do not conflict with the exclusive license to PATENT RIGHTS and KNOW-HOW granted in Article 2 herein.

  
 - 3 -

	 	j.	“FOUNDERS’ SHARES” shall mean common stock of MERIX issued or reserved for issue by MERIX prior to closing a round of equity financing with outside
investors. The fair market value and price of FOUNDERS’ SHARES shall be deemed to be one cent [$0.01] per share. DUKE and MERIX agree that all FOUNDERS’ SHARES issued shall be dilutable to the same extent upon each stage of subsequent
financing of MERIX and that the total number of FOUNDERS’ SHARES, issued or reserved for issuance, will be two million five hundred thousand [2,500,000] shares. 

 

	 	k.	“EFFECTIVE DATE” shall mean January 10, 2000. 

 ARTICLE 2 - LICENSE 
 2.01 - DUKE hereby grants to the MERIX and MERIX
hereby accepts from DUKE, upon the terms and conditions herein specified, an exclusive worldwide license under the PATENT RIGHTS and KNOW-HOW to make, have made, use, import, offer to sell, sell, offer to
provide and provide LICENSED PRODUCTS. Such license is worldwide to the full end of the term as provided in Article 11.01 hereof, unless sooner terminated as hereinafter provided. DUKE hereby represents that it has the full right and authority to
enter into this AGREEMENT, to grant the licenses provided herein and to perform its other obligations hereunder. 
 2.02 - MERIX
shall have the right to grant sub-licenses. Any such sub-licenses shall be subject to terms of this AGREEMENT. Royalties paid to DUKE for NET SALES of LICENSED PRODUCTS
by sublicensees shall be equal to the royalties that would have been paid to DUKE if LICENSED PRODUCTS were sold directly by MERIX. The terms of any non-cash
sub-licenses will be negotiated by DUKE and MERIX. MERIX agrees to be responsible for the payment to DUKE of royalties on funds received by MERIX from its sublicensees and for using commercially reasonable
efforts to enforce the terms of the sublicense agreements. If, for any reason, this AGREEMENT is terminated, MERIX agrees to assign all such sublicenses directly to DUKE. 
 2.03 - It is agreed that, notwithstanding any provisions herein, DUKE is free to use the 1101 INVENTION, the 1215 INVENTION and PATENT RIGHTS for its own
non-commercial educational, teaching, research and clinical purposes without restriction and without payment of royalties or other fees. 

2.04 - Nothing in this AGREEMENT shall be construed to grant to DUKE any rights in the inventions, discoveries, technology, patent rights
or other intellectual property developed by or for MERIX or its AFFILIATES or sub-licensees and which are not covered by the PATENT RIGHTS or KNOW-HOW. 

  
 - 4 -

 2.05 - Within [**] days following the execution of this AGREEMENT and thereafter during the
period of this AGREEMENT, DUKE agrees to provide MERIX with copies of all technical know-how it may have or later obtain relative to the PATENT RIGHTS or KNOW-HOW, and copies of any and all patents or patent
applications owned or controlled by DUKE covering the PATENT RIGHTS or KNOW-HOW or the use of the PATENT RIGHTS or KNOW-HOW or processes for the manufacture of the
LICENSED PRODUCTS, including all Patent Office actions received and amendments filed, if any, relative thereto. 
 ARTICLE 3 -
OPTION 
 3.01 - DUKE hereby grants to MERIX an exclusive option to obtain an exclusive, worldwide, royalty bearing license
to all new OPTIONED INVENTIONS. DUKE shall notify MERIX within [**] of the date that DUKE learns that an OPTIONED INVENTION has been made. MERIX shall then have a period of [**] days [the “OPTION PERIOD”] to inform DUKE in writing that
MERIX wishes to exercise its option to negotiate a license to the OPTIONED INVENTION. If MERIX does not notify DUKE that it wishes to exercise its option within the OPTION PERIOD, or if MERIX informs DUKE that it does not wish to exercise its
option, the option will expire at the end of the OPTION PERIOD, and DUKE will be free to dispose of the OPTIONED INVENTIONS in DUKE’s sole discretion. If MERIX notifies DUKE in writing during the OPTION PERIOD that MERIX wishes to exercise its
option, DUKE and MERIX will negotiate in good faith for [**] days from the date that DUKE receives notification from MERIX [the “NEGOTIATION PERIOD”] to conclude a license agreement for the OPTIONED INVENTION on commercially reasonable
terms and substantially in accordance with Exhibit A hereto. If the parties cannot agree on terms by the end of the NEGOTIATION PERIOD, DUKE will be under no obligation to continue negotiations and will be free to dispose of the OPTIONED
INVENTION on terms no more favorable than offered to MERIX. 
 ARTICLE 4 - CONSIDERATION 

4.01 - As consideration for the rights granted by DUKE in this AGREEMENT, MERIX shall transfer to DUKE upon execution of this AGREEMENT,
ownership of five hundred thousand [500,000] fully vested, non-voting FOUNDERS’ SHARES, equal to twenty percent [20%] of the total FOUNDERS’ SHARES issued or reserved for issuance by MERIX. At the
time that MERIX closes on the sale of capital stock to the public through a registration statement registered under the Securities Act of 1933, as amended, DUKE’s shares will convert to voting shares of common stock. 

4.02 - DUKE shall be entitled to have one person reasonably acceptable to MERIX attend all meetings of the Board of Directors of MERIX as
an observer for a period of [**] years from the EFFECTIVE DATE of this AGREEMENT. 

  
 - 5 -

 4.03 - As further consideration for the rights granted by DUKE in this AGREEMENT, at the
times and in the manner set forth hereinafter, MERIX shall pay to DUKE a royalty on NET SALES of LICENSED PRODUCTS. Such royalty shall be at the rate of [**] percent ([**]%) of NET SALES of LICENSED PRODUCTS sold by MERIX, by AFFILIATES, or by
sublicensees; provided, however, that MERIX shall not be obliged to pay a total royalty on any LICENSED PRODUCT to all parties in excess of [**] percent ([**]%) of NET SALES. In the event that MERIX’s total royalty obligation on a LICENSED
PRODUCT exceeds [**]percent ([**]%) the amount of royalty paid to all parties will be decreased proportionately so that the total royalty obligation is reduced to [**] percent ([**]%); however, in no event shall the royalty paid to DUKE be less than
[**] percent ([**]%). For avoidance of doubt, the parties agree that any other royalties due to DUKE for the LICENSED PRODUCTS based on other agreements between DUKE and MERIX shall (including the license for the inventions described in Duke Office
of Science and Technology File #[**]) be included in the calculation of total royalties set forth in this paragraph. 
 4.04 -
MERIX will pay to DUKE a minimum annual royalty of [**] dollars ($[**]) per year beginning the calendar year that begins on the second January 1 after the earlier of (1) the approval of the first LICENSED PRODUCT by the FDA or a comparable
regulatory authority in a foreign country or (2) the first sale of a LICENSED PRODUCT that does not require FDA approval. Any payments made by MERIX pursuant to Section 4.03 hereof for a particular calendar year shall be credited to the
minimum annual royalty for such calendar year. 
 4.05 - All consideration paid to DUKE under Article 4.01 will be allocated as
follows: [**] percent [[**]%] as consideration for the license granted to the 1215 INVENTION and related PATENT RIGHTS under Article 2 herein, [**] percent [[**]%] as consideration for the license granted to the 1101 INVENTION and related PATENT
RIGHTS under Article 2 herein, and [**] percent [[**]%] as consideration for the option granted under Article 3 herein. 

ARTICLE 5 - RECORDS AND REPORTS 
 5.01 - MERIX shall render to DUKE prior to February 28th of each year a written account of progress made toward fulfillment of any due diligence requirements and commercialization of PATENT RIGHTS
pursuant to Article 6. 
 5.02 - MERIX shall render to DUKE prior to February 28th and August 31st of each year a written account of the NET SALES of LICENSED PRODUCTS
subject to royalty hereunder made during the prior six month period ending December 31st and June 30th, respectively, and shall simultaneously pay to DUKE the royalties due on such NET SALES in United States Dollars. Reports tendered shall include the calculation of royalties by LICENSED PRODUCT by
country in substantially the format provided in Appendix A hereto]. Minimum annual royalties, if any, which are due DUKE for any calendar year, shall be paid by MERIX along with the written report due on February 28th of each year. 

5.03 - MERIX will make all payments on or before the date required by the terms of this AGREEMENT, or within [**] days of any invoice
date on invoices received from DUKE. If LICENSEE has not paid any amount due to DUKE in accordance with this Article, DUKE shall increase the amount due (in US Dollars) by an annual percentage rate equal to [**]%. Such increase(s) shall compound
monthly until such time as the LICENSEE has met the full financial obligation due at the time of the next payment or invoice due date. 

  
 - 6 -

 5.04 - MERIX shall keep full, true and accurate books of accounts and other records
containing all particulars which may be necessary to properly ascertain and verify the royalties payable by it hereunder. Upon DUKE’s request, MERIX shall permit an independent Certified Public Accountant selected by DUKE (except one to whom
MERIX has some reasonable objection) to have access during ordinary business hours to such of MERIX’s records as may be necessary to determine, in respect of any quarter ending not more than [**] years prior to the date of such request, the
correctness of any report and/or payment made under this AGREEMENT. Such Certified Public Accountant shall execute a written nondisclosure agreement reasonably acceptable to MERIX. 

5.05 - During the term of this AGREEMENT, representatives of DUKE will meet with representatives of MERIX at times and places mutually
agreed upon to discuss the progress and results, as well as ongoing plans, with respect to the evaluation and development of the PATENT RIGHTS licensed to MERIX; provided, however, that should DUKE’s personnel be required by MERIX to consult
with MERIX outside of Durham County, North Carolina, MERIX will reimburse reasonable travel and living expenses incident thereto. 
 ARTICLE 6 - DUE DILIGENCE REQUIREMENTS 
 6.01 - MERIX shall use reasonable
commercial diligence in performing research and development to bring LICENSED PRODUCTS to market through a thorough, vigorous, and diligent program for exploitation of the PATENT RIGHTS, to develop manufacturing capabilities, and to continue active,
diligent marketing efforts for LICENSED PRODUCTS throughout the term of this AGREEMENT, and to vigorously sublicense PATENT RIGHTS for applications MERIX will not pursue throughout the life of this AGREEMENT. 

6.02 - In addition, MERIX shall raise at least ONE MILLION DOLLARS [$1,000,000] in equity investment prior to or within three months of
the EFFECTIVE DATE of this AGREEMENT. 
 6.03 - DUKE may terminate this AGREEMENT or convert this AGREEMENT to a non-exclusive AGREEMENT if MERIX fails to meet any of the commercialization milestones set forth in Article 6.01 or 6.02 and MERIX has failed to cure such failure within [**] days after receiving written notice from
DUKE of such failure. 
 ARTICLE 7 - PATENTS 
 7.01 - Upon execution of this License Agreement, MERIX will assume the primary responsibility for applying for, seeking prompt issuance of, and maintaining the Patent Rights during the term of the
Agreement. MERIX shall diligently and in a timely manner provide DUKE with copies of all documents relating to the prosecution, maintenance, and validity of the PATENT RIGHTS. MERIX shall consult with DUKE in such prosecution and maintenance, and
shall diligently seek strong and broad claims under the Patent Rights and shall not abandon prosecution of any patent application or any of the claims of the Patent Rights without first notifying DUKE in a timely manner of MERIX’s intention and
reason therefor, and providing DUKE with reasonable opportunity to assume responsibility for prosecution and maintenance of the patents. 

  
 - 7 -

 7.02 - MERIX shall be responsible for and pay all costs and expenses incurred during the
term of this Agreement, for the preparation, filing, prosecution, issuance and maintenance of the Patent Rights. MERIX shall not allow Patent Rights to become abandoned due to nonpayment of fees without first affording DUKE the opportunity to assume
responsibility for further costs and expenses incurred relating to said Patent Rights. 
 7.03 - In the event that DUKE assumes
responsibility for prosecution and maintenance of the Patent Rights pursuant to Section 7.01 or 7.02 above, MERIX shall provide reasonable technical assistance to DUKE in the further prosecution of the Patent Rights. 

7.04 - In the event that this Agreement is terminated pursuant to Article 11 herein, the sole responsibility for applying for, seeking
prompt issuance of, and maintaining the Patent Rights shall revert to the DUKE, and DUKE shall pay expenses subsequently incurred for the preparation, filing, prosecution, issuance and maintenance of the Patent Rights. In the event that
responsibility for patent prosecution reverts to DUKE as specified in this section 7.04, MERIX shall, at its own expense, transfer all pertinent documents and materials related to the PATENT RIGHTS to DUKE in a timely manner. 

ARTICLE 8 - INFRINGEMENT BY THIRD PARTIES 
 8.01 - Upon learning of the infringement of PATENT RIGHTS by a third party, the party learning of such infringement shall promptly inform the other party in writing of that fact along with any evidence
available pertaining to the infringement. MERIX may at its own expense take whatever steps are necessary to stop the infringement and recover damages. In such case, MERIX will keep DUKE informed of the steps taken and the progress of any legal
actions taken. MERIX will pay to DUKE royalties pursuant to Article 4.03 on any such damages recovered as consideration for lost sales of LICENSED PRODUCTS that are in excess of legal expenses incurred by MERIX in enforcing its PATENT RIGHTS. If
MERIX does not undertake, within [**] days of notice, to enforce the PATENT RIGHTS against the infringing party, DUKE shall have the right, at its own expense to take whatever steps are necessary to stop the infringement and recover damages, and
shall be entitled to retain damages so recovered (after reimbursing MERIX for any of its expenses in cooperating with DUKE in prosecuting such infringement). 
 ARTICLE 9 - GOVERNMENT CLEARANCE AND EXPORT 
 9.01 - MERIX agrees to use
its best efforts to have the LICENSED PRODUCTS cleared for marketing and sale in those countries in which MERIX intends to sell LICENSED PRODUCTS by the responsible government agencies requiring such clearance. Where such clearance requires payment
of taxes or fees, MERIX shall maintain full responsibility for that payment, which shall not be creditable against any other amounts due under this AGREEMENT. To accomplish said clearances at the earliest possible date, MERIX agrees to file,
according to the usual practice of MERIX, any necessary data with said government agencies. 
 9.02 - This AGREEMENT is subject
to all of the United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities and technology. 

  
 - 8 -

 ARTICLE 10 - PUBLICATION 

10.01 - MERIX agrees that the right of publication of the 1101 INVENTION and of the 1215 INVENTION and information in related PATENT
RIGHTS shall reside in the inventors and other staff of DUKE. DUKE shall use reasonable efforts to provide MERIX a review copy of such publications [**] days in advance of submission for publication or public disclosure, but such prior review by
MERIX will be in no way construed as a right to restrict such publication. Such review shall be granted solely so that DUKE and MERIX can perfect patent protection prior to public disclosure. MERIX shall also have the right to publish and/or co-author any publication on the 1101 INVENTION and the 1215 INVENTION based upon data developed by MERIX. 
 ARTICLE 11 - DURATION AND TERMINATION 
 11.01 - This AGREEMENT shall become
effective upon the EFFECTIVE DATE, and unless sooner terminated in accordance with any of the provisions herein, shall remain in full force and effect for the longer of: (i) the life of the last-to-expire of the patents included in the PATENT RIGHTS or any patents issued on KNOW-HOW; or (ii), so long as one or more FOUNDERS is employed by DUKE, ten (10) years from the EFFECTIVE DATE hereof.
Upon the expiration of this AGREEMENT, DUKE shall grant MERIX an exclusive, worldwide, fully paid license, with the right to grant sub-licenses, under the KNOW-HOW to
make, have made, use, import, offer to sell, sell, offer to provide and provide LICENSED PRODUCTS. 
 11.02 - MERIX may
terminate this AGREEMENT by giving DUKE written notice at least three (3) months prior to such termination, and thereupon terminate the manufacture, use or sale of LICENSED PRODUCTS. 

11.03 - Either party may immediately terminate this AGREEMENT for fraud, willful misconduct, or illegal conduct of the other party that
materially adversely affects such party upon written notice of same to that other party. Except as provided above, if either party fails to fulfill any of its material obligations under this AGREEMENT, the
non-breaching party may terminate this AGREEMENT, upon written notice to the breaching party, as provided below. Such notice must contain a full description of the event or occurrence constituting a breach of
this AGREEMENT. The party receiving notice of the breach shall submit a plan to cure such breach to the non-defaulting party within [**] days of receipt of such notice. The plan shall be subject to the
reasonable acceptance, rejection or modification by the non-defaulting party within [**] days of receipt of the plan. The defaulting party shall have the opportunity to cure that breach in accordance with the
terms of the accepted plan. If the breach is not cured within that time, the termination will be effective as of the end of the cure period set forth in the accepted plan. A party’s ability to cure a breach will apply only to the first two
breaches properly noticed under the terms of this AGREEMENT, regardless of the nature of those breaches. Any subsequent breach by that party will entitle the other party to terminate this AGREEMENT upon proper notice. 

11.04 - Upon the termination of this AGREEMENT, MERIX may notify DUKE of the amount of LICENSED PRODUCTS MERIX then has on hand and MERIX
shall then have a license to sell that amount of LICENSED PRODUCTS, but no more, provided MERIX shall pay the royalty thereon at the rate and at the time provided for herein. 

  
 - 9 -

 11.05 - If during the term of this Agreement, MERIX shall become bankrupt or insolvent or if
the business of MERIX shall be placed in the hands of a receiver or trustee, whether by the voluntary act of MERIX or otherwise, or if MERIX shall cease to exist as an active business, this Agreement shall immediately terminate as though with MERIX
breach, and DUKE shall have all the remedies and rights available to it for termination with cause; provided, however, that this provision shall not apply to a reorganization of MERIX under Chapter 11 of the United States Bankruptcy Code.

 ARTICLE 12 - LAW TO GOVERN 
 12.01 - This AGREEMENT shall be construed and enforced in accordance with the laws of the State of North Carolina. 
 ARTICLE 13 - NOTICES 
 13.01 - Notice hereunder shall be deemed sufficient
if personally delivered, if given by registered mail, postage prepaid, or by national overnight courier, charges prepaid, and in each instance addressed to the party to receive such notice at the address given below, or such other address as may
hereafter be designated by notice in writing. 
  

			
	DUKE	 	MERIX
		
	Office of Science and Technology	 	P.O. Box 14509
	Duke University	 	Research Triangle Park, NC 27709
	Room 230, North Building	 	ATTENTION: CEO
	Box 90083	 	
	Durham, NC 27708	 	
		
	cc: Office of the University Counsel	 	cc: Fred D. Hutchison, Esquire
	Duke University Medical Center	 	Hutchison & Mason PLLC
	DUMC Box 3024	 	Suite 100
	2400 Pratt Street, Suite 4000	 	3110 Edwards Mill Road
	Durham NC 27710	 	Raleigh NC 27612

 13.02 - Information and transactions exchanged between the parties in relation to financial consideration
contemplated under this AGREEMENT, including but not limited to royalty reports and payments, shall be tendered to the following offices of each party respectively: 
  

			
	DUKE	 	MERIX
	Office of Science and Technology	 	P.O. Box 14509
	Attn.: Financial Administrator	 	Research Triangle Park, NC 27709
	Room 230, North Building	 	ATTENTION: CEO
	Box 90083	 	
	Durham NC 27708	 	

  
 - 10 -

 ARTICLE 14 - ASSIGNMENT 

14.01 - This AGREEMENT shall be binding upon and inure to the benefit of the respective successors and assigns of the parties hereto.
However, MERIX may not assign its rights in this AGREEMENT without approval by DUKE, such approval not to be unreasonably withheld; provided, however, that no such approval shall be required from DUKE if this AGREEMENT is assigned in connection with
the sale of all or substantially all of the assets or stock of MERIX, whether by merger, acquisition or otherwise. 
 ARTICLE
15 - INDEMNITY, INSURANCE, REPRESENTATIONS, STATUS 
 15.01 - MERIX agrees to indemnify, hold harmless and defend DUKE, its
officers, employees, and agents, against any and all claims, suits, losses, damages, costs, fees, and expenses asserted by third parties, both government and non-government, resulting from or arising out of
the exercise of the license granted under this AGREEMENT. MERIX shall not be responsible for the negligence or intentional wrong doing of DUKE. 
 15.02 - MERIX shall maintain in force at its sole cost and expense, with reputable insurance companies, general liability insurance and products liability insurance coverage in amounts customary for
companies similarly situated in the same industry. DUKE shall have the right to ascertain from time to time that such coverage exists, such right to be exercised in a reasonable manner. In lieu of said coverage, DUKE agrees to consider the existence
of an adequate self-insurance program as an acceptable alternative. 
 15.03 - NOTHING IN THIS AGREEMENT SHALL BE DEEMED TO BE A
REPRESENTATION OR WARRANTY BY DUKE OF THE VALIDITY OF ANY OF THE PATENTS OR THE ACCURACY, SAFETY, EFFICACY, OR USEFULNESS, FOR ANY PURPOSE, OF ANY PATENT RIGHTS. DUKE SHALL HAVE NO OBLIGATION, EXPRESS OR IMPLIED, TO SUPERVISE, MONITOR, REVIEW OR
OTHERWISE ASSUME RESPONSIBILITY FOR THE PRODUCTION, MANUFACTURE, TESTING, MARKETING OR SALE OF ANY LICENSED PRODUCT, AND DUKE SHALL HAVE NO LIABILITY WHATSOEVER TO MERIX OR ANY THIRD PARTIES FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE, OF ANY
KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSESSED OR ASSERTED AGAINST, OR ANY OTHER LIABILITY INCURRED BY OR IMPOSED UPON MERIX OR ANY OTHER PERSON OR ENTITY, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM: 

 

	 	a.	the production, use, or sale of any LICENSED PRODUCT; 

  

	 	b.	the use of any PATENT RIGHTS by MERIX or its sublicensees; or 

  

	 	c.	any advertising or other promotional activities by MERIX with respect to any of the foregoing. 

15.04 - Neither party hereto is an agent of the other party for any purpose whatsoever. 

  
 - 11 -

 ARTICLE 16 - USE OF A PARTY’S NAME 

16.01 - Neither party will, without the prior written consent of the other party: 

 

	 	a.	use in advertising, publicity or otherwise, any trade-name, personal name, trademark, trade device, service mark, symbol, or any abbreviation, contraction or simulation
thereof owned by the other party; or 

  

	 	b.	represent, either directly or indirectly, that any product or service of the other party is a product or service of the representing party or that it is made in
accordance with or utilizes the information or documents of the other party. 

 ARTICLE 17 - SEVERANCE, WAIVER
AND ALTERATION 
 17.01 - Each clause of this AGREEMENT is a distinct and severable clause and if any clause is deemed
illegal, void or unenforceable, the validity, legality or enforceability of any other clause or portion of this AGREEMENT will not be affected thereby. 
 17.02 - The failure of a party in any instance to insist upon the strict performance of the terms of this AGREEMENT will not be construed to be a waiver or relinquishment of any of the terms of this
AGREEMENT, either at the time of the party’s failure to insist upon strict performance or at any time in the future, and such terms will continue in full force and effect. 

17.03 - Any alteration, modification, or amendment to this AGREEMENT must be in writing and signed by both parties. 

ARTICLE 18 - CONFIDENTIALITY 
 18.01 - During the term of this AGREEMENT and for a period of [**] years following the expiration of termination of this AGREEMENT, DUKE and MERIX each agree to treat any confidential information
disclosed to it by the other party to this AGREEMENT with reasonable care and to avoid disclosure of such information to any other person, firm or corporation, except AFFILIATES, and either party shall be liable for unauthorized disclosure or
failure to exercise such reasonable care. Neither party shall have an obligation, with respect to confidential information disclosed to it, or any part thereof, which: 
 (a) is already known to the party at the time of the disclosure; 
 (b) becomes
publicly known without the wrongful act or breach of this AGREEMENT by the party; 
 (c) is rightfully received by the party
from a third party on a non-confidential basis; 
 (d) is subsequently and independently
developed by employees of the party who had no knowledge of the information, as verified by written records; or 
 (e) is
approved for release by written authorization of the party disclosing the information. 

  
 - 12 -

 18.02 - DUKE and MERIX agree that any information to be treated as confidential information
under this Article 18 must be disclosed in writing or in another tangible medium and must be clearly marked “CONFIDENTIAL”. Information disclosed orally must be summarized and reduced to writing and communicated to the other party within
[**] days, and the other party agrees that such disclosed information shall be deemed confidential. 
 18.03 - Notwithstanding
the foregoing, MERIX shall have the right to use and disclose any Confidential Information related to the PATENT RIGHTS and KNOW-HOW to investors, prospective investors, employees and agents with a need to
know, collaborators, prospective collaborators and other third parties in the chain of manufacturing and distribution provided that MERIX obtains from such parties written confidentiality agreements the provisions of which are at least as strenuous
as those provided in this Article 18. If a party refuses to execute a written confidentiality agreement, MERIX may request from DUKE that such requirement be waived, such consent to waiver not to be unreasonably withheld by DUKE. 

ARTICLE 19 - TRANSFER OF MATERIALS 
 19.01 - Any transfer of materials between DUKE and MERIX in connection with this AGREEMENT shall be made under the terms of the Master Materials Transfer Agreement [MMTA], said MMTA being incorporated in
its entirety as Appendix B of the present AGREEMENT. 
 ARTICLE 20 - TITLES 

20.01 - All titles and article headings contained in this AGREEMENT are inserted only as a matter of convenience and reference. They do
not define, limit, extend or describe the scope of this AGREEMENT or the intent of any of its provisions. 
 ARTICLE 21 -
ENTIRE UNDERSTANDING 
 21.01 - This AGREEMENT represents the entire understanding between the parties with respect to the
subject matter hereof, and supersedes all other agreements, express or implied, between the parties concerning the 1101 INVENTION, the 1215 INVENTION, and PATENT RIGHTS. 
 REMAINDER OF THIS PAGE LEFT BLANK INTENTIONALLY. 
 SIGNATURES ON NEXT PAGE.

  
 - 13 -

 IN WITNESS WHEREOF, the parties have caused these presents to be executed in
duplicate as of the date and year first above written. 
  

					
	SEAL	 	DUKE UNIVERSITY
			
		 	By:	 	 /s/ Robert Taber

		 		 	  Robert Taber
		 		 	  Director, Office of Science & Technology
			
		 	Date:	 	 1-10-2000

		
	SEAL	 	MERIX BIOSCIENCE, INC.
			
		 	By:	 	 /s/ John C. Irick

		 	Title:	 	 Chief Executive Officer

		 	Date:	 	 1-10-2000

  
 - 14 -

 Exhibit A to License Agreement for 1101 INVENTION and 1215 INVENTION 

LICENSE AGREEMENT 
 THIS LICENSE AGREEMENT (the “AGREEMENT”) made and entered into this              day of
            , 20    , by and between DUKE UNIVERSITY, a North Carolina not-for-profit
corporation, (hereinafter called “DUKE”), having its principal office at Durham, North Carolina 27708, and MERIX BIOSCIENCE, INC. a Delaware corporation organized under the laws of Delaware (hereinafter called “MERIX”), having a
mailing address at P.O. Box 14509, Research Triangle Park, North Carolina 27709. 
 WHEREAS,
                                         
                                        are inventors
of an invention [the “             INVENTION” hereinafter] described in Duke Office of Science and Technology File
#             and in related patent applications defined hereinafter; and 
 WHEREAS, DUKE has the right to grant licenses to the              INVENTION under PATENT RIGHTS (as hereinafter defined), and wishes to have the
inventions covered by the PATENT RIGHTS utilized in the public interest; and 
 [WHEREAS, the
             Invention was made with U.S. Government support and, notwithstanding any use of descriptive terms within this AGREEMENT such as “exclusive”, the U. S. Government has
certain rights in the              Invention under 37 C.F.R. Section 401; and] 
 WHEREAS, DUKE represents that it is the sole owner of the entire right, title and interest in and to said inventions and PATENT RIGHTS[, subject to the U.S. Government’s rights specified above]; and

 WHEREAS, MERIX represents that it intends to develop and commercialize the Patents Rights so that products made under the
PATENT RIGHTS shall become available to the public. 
 NOW THEREFORE, in consideration of the premises and the faithful
performance of the covenants herein contained, IT IS AGREED: 
 ARTICLE 1 - DEFINITIONS 

1.01 - For the purposes of this AGREEMENT, and solely for that purpose, the terms and phrases set forth hereinafter in capital letters
shall be defined as follows: 
  

	 	a.	“FIELD OF USE 1” shall mean the use of the know-how and patent rights, cell lines, substances and material produced by
cell lines and included in PATENT RIGHTS in the field of autoimmune diseases or disorders, infectious diseases or cancer in humans or animals and useful for: (i) active and/or adoptive immunological intervention intended for therapy or
prevention; (ii) monitoring of immunological parameters for diagnosis, therapy or the development of candidate interventions; or (iii) discovery of new antigens for diagnosis, monitoring or therapy. 

  
 - 1 -

	 	b.	“PATENT RIGHTS” shall mean all U.S. and foreign patent applications filed to protect the
             INVENTION and any patent now issued or hereafter issuing on any such patent application, substitutes, continuations, extensions, renewals, reissues, reexaminations, additions, continuations-in-part, divisionals, or reissues thereof and any patent revalidations, registrations, supplementary protection certificates, patents of importation or
cautionary notices thereof in connection with the              Invention. As of the EFFECTIVE DATE of this AGREEMENT, PATENT RIGHTS related to the
             INVENTION consist of the following: [To Be Completed] 

  

	 	c.	“Know-How” shall mean any research information, technical information, technical data or other confidential information not in the public domain made or that
may be made by one of the inventors of the              INVENTION and/or one of them and others working under the supervision of one of them, while students or employees of DUKE prior to or
during the term of this AGREEMENT, which relate to and are necessary for the practice of the PATENT RIGHTS. For avoidance of doubt, Know-How shall include all unpatented and unpatentable inventions,
technology, cell lines, biological materials, compounds, probes, sequences, and methods necessary for the practice of the PATENT RIGHTS under this AGREEMENT. Know-How shall not, however, include any such
materials or information or any uses of such materials and information that DUKE cannot provide to MERIX on either an exclusive or non-exclusive basis because of other legal obligations of DUKE pursuant to
sponsored research, clinical research, material transfer, confidentiality or other agreements. 

  

	 	d.	“VALID CLAIM” means a claim of an issued patent which has not lapsed or become abandoned or been declared invalid or unenforceable by a court of competent
jurisdiction or an administrative agency for which there is no right of appeal or for which the right of appeal is waived. 

  

	 	e.	“LICENSED PRODUCT” shall mean any product which is produced or sold by MERIX that utilizes the KNOW-HOW or that
infringes one or more VALID CLAIMS of the PATENT RIGHTS, and which is intended for use in, or is used in, the FIELD. 

  

	 	f.	“NET SALES” shall mean the total invoiced sales of LICENSED PRODUCTS sold by MERIX, less the following sums actually paid or credited by MERIX as shall be
detailed in MERIX’s reports made pursuant to Section 5.02 of this AGREEMENT: 

  

	 	(a)	trade, quantity or cash discounts or commissions allowed in amounts customary in the trade; 

 

	 	(b)	any tax, excise or other governmental charge upon or measured by the production, sale, transportation, delivery or use and duties imposed on the import of LICENSED
PRODUCTS included in such amount; 

  
 - 2 -

	 	(c)	outbound transportation charges prepaid or allowed on the cost of shipping to customers, if any; and 

 

	 	(d)	credits or allowances, if given or made for LICENSED PRODUCTS, price adjustments, returns, rejections, recalls or destructions (voluntarily made by or requested or made
by an appropriate government agency, subdivision or department) of LICENSED PRODUCTS previously delivered. 

 LICENSED PRODUCTS
used by MERIX for its own use in the FIELD, LICENSED PRODUCTS sold to Affiliates, and internal sales for use in service businesses in arms length transactions shall be considered to be NET SALES for purposes of computing royalty obligations, except
such LICENSED PRODUCT used for non-revenue producing activity such as promotional items or field trials shall not be considered to be NET SALES. 

 

	 	j.	“AFFILIATE” shall mean any entity which controls, is controlled by or is under common control with MERIX. An entity shall be regarded as in control of another
entity if it owns or controls more than fifty percent (50%) of the voting power of the entity. 

  

	 	k.	“FOUNDERS” shall mean H. Kim Lyerly, Eli Gilboa, Clay Smith, and Bruce Sullenger, the scientific founders of MERIX, and “FOUNDER” shall mean any of
these individuals. 

  

	 	l.	“EFFECTIVE DATE” shall mean
                                        .

 ARTICLE 2 - LICENSE 
 2.01 - DUKE hereby grants to MERIX and MERIX hereby accepts from DUKE, upon the terms and conditions herein specified, an exclusive worldwide license under the PATENT RIGHTS and KNOW-HOW to make, have made, use, import, offer to sell, sell, offer to provide and provide LICENSED PRODUCTS. Such license is worldwide to the full end of the term as provided in Article 11.01 hereof, unless sooner
terminated as hereinafter provided. DUKE hereby represents that it has the full right and authority to enter into this AGREEMENT, to grant the licenses provided herein and to perform its other obligations hereunder. 

2.02 - MERIX shall have the right to grant sub-licenses. Any such
sub-licenses shall be subject to terms of this AGREEMENT. Royalties paid to DUKE for NET SALES of LICENSED PRODUCTS by sublicensees shall be equal to the royalties that would have been paid to DUKE if LICENSED
PRODUCTS were sold directly by MERIX. The terms of any non-cash sub-licenses will be negotiated by DUKE and MERIX. MERIX agrees to be responsible for the payment to DUKE
of royalties on funds received by MERIX from its sublicensees and for using commercially reasonable efforts to enforce the terms of the sublicense agreements. If, for any reason, this AGREEMENT is terminated, MERIX agrees to assign all such
sublicenses directly to DUKE. 

  
 - 3 -

 2.03 - It is agreed that, notwithstanding any provisions herein, DUKE is free to use the
             INVENTION and PATENT RIGHTS for its own non-commercial educational, teaching, research and clinical purposes without restriction and
without payment of royalties or other fees. 
 2.04 - Nothing in this AGREEMENT shall be construed to grant to DUKE any rights
in the inventions, discoveries, technology, patent rights or other intellectual property developed by or for MERIX or its AFFILIATES or sub-licensees and which not covered by the PATENT RIGHTS or KNOW-HOW.

 2.05 - Within [**] days following the execution of this AGREEMENT and thereafter during the period of this AGREEMENT, DUKE
agrees to provide MERIX with copies of all technical know-how it may have or later obtain relative to the PATENT RIGHTS or KNOW-HOW, and copies of any and all patents or patent applications owned or controlled
by DUKE covering the PATENT RIGHTS or KNOW-HOW or the use of the PATENT RIGHTS or KNOW-HOW or processes for the manufacture of the LICENSED PRODUCTS, including all
Patent Office actions received and amendments filed, if any, relative thereto. 
 ARTICLE 3 - ROYALTIES ON NET SALES OF
LICENSED PRODUCTS 
 3.01 - As consideration for the rights granted by DUKE in this AGREEMENT, at the times and in the
manner set forth hereinafter, MERIX shall pay to DUKE a royalty on NET SALES of LICENSED PRODUCTS. Such royalty shall be at the rate of
                     percent [    %] of NET SALES of LICENSED PRODUCTS sold by MERIX, by AFFILIATES, or by sublicensees.
[Royalty stacking to be negotiated] 
 3.02 - MERIX will pay to DUKE a minimum annual royalty of
                     dollars ($            ) per year beginning
                                        .

 ARTICLE 4 - MILESTONE BASED ROYALTIES 
 4.01 - As further consideration for the rights granted by DUKE in this AGREEMENT, MERIX shall pay to DUKE milestone based royalties within [**] days of the attainment by MERIX, its AFFILIATES, or its
sublicensees of the commercial milestones specified below. No such milestone payments shall be credited towards other royalties or minimum royalties due. [To Be Negotiated] 

ARTICLE 5 - RECORDS AND REPORTS 
 5.01 - MERIX shall render to DUKE prior to February 28th of each year a written account of progress made toward fulfillment of any due diligence requirements and commercialization of PATENT RIGHTS
pursuant to Article 6. 
 5.02 - MERIX shall render to DUKE prior to February 28th and August 31st of each year a written account of the NET SALES of LICENSED PRODUCTS
subject to royalty hereunder made during the prior six month period ending December 31st and June 30th, respectively, and shall simultaneously pay to DUKE the royalties due on such NET SALES in United States Dollars. Reports tendered shall include the calculation of royalties by LICENSED PRODUCT by
country in substantially the format provided in Appendix A hereto. Minimum annual royalties, if any, which are due DUKE for any calendar year, shall be paid by MERIX along with the written report due on February 28th of each year. 

  
 - 4 -

 5.03 - MERIX will make all payments on or before the date required by the terms of this
AGREEMENT, or within [**] days of any invoice date on invoices received from DUKE. If LICENSEE has not paid any amount due to DUKE in accordance with this Article, DUKE shall increase the amount due (in US Dollars) by an annual percentage rate equal
to [**]%. Such increase(s) shall compound monthly until such time as the LICENSEE has met the full financial obligation due at the time of the next payment or invoice due date. 

5.04 - MERIX shall keep full, true and accurate books of accounts and other records containing all particulars which may be necessary to
properly ascertain and verify the royalties payable by it hereunder. Upon DUKE’s request, MERIX shall permit an independent Certified Public Accountant selected by DUKE (except one to whom MERIX has some reasonable objection) to have access
during ordinary business hours to such of MERIX’s records as may be necessary to determine, in respect of any quarter ending not more than [**] years prior to the date of such request, the correctness of any report and/or payment made under
this AGREEMENT. Such Certified Public Accountant shall execute a written non-disclosure agreement reasonably acceptable to MERIX. 
 5.05 - During the term of this AGREEMENT, representatives of DUKE will meet with representatives of MERIX at times and places mutually agreed upon to discuss the progress and results, as well as ongoing
plans, with respect to the evaluation and development of the PATENT RIGHTS licensed to MERIX; provided, however, that should DUKE’s personnel be required by MERIX to consult with MERIX outside of Durham County, North Carolina, MERIX will
reimburse reasonable travel and living expenses incident thereto. 
 ARTICLE 6 - DUE DILIGENCE REQUIREMENTS 

6.01 - MERIX shall use reasonable commercial diligence in performing research and development to bring LICENSED PRODUCTS to market
through a thorough, vigorous, and diligent program for exploitation of the PATENT RIGHTS, to develop manufacturing capabilities, and to continue active, diligent marketing efforts for LICENSED PRODUCTS throughout the term of this AGREEMENT, and to
vigorously sublicense PATENT RIGHTS for applications MERIX will not pursue throughout the life of this AGREEMENT. 
 6.02 -
[To Be Negotiated] 
 6.03 - DUKE may terminate this AGREEMENT or convert this AGREEMENT to a non-exclusive AGREEMENT if MERIX fails to meet any of the requirements of this Article and MERIX has failed to cure such failure within [**] days after receiving written notice from DUKE of such failure. 

ARTICLE 7 - PATENTS 
 7.01 - Upon execution of this License Agreement, MERIX will assume the primary responsibility for applying for, seeking prompt issuance of, and maintaining the Patent Rights during the term of the
Agreement. MERIX shall diligently and in a timely manner provide DUKE with copies of all documents relating to the prosecution, maintenance, and validity of the PATENT RIGHTS. MERIX shall consult with DUKE in such prosecution and maintenance, and
shall diligently seek strong and broad claims under the Patent Rights and shall not abandon prosecution of any patent application or any of the claims of the Patent Rights without first notifying DUKE in a timely manner of MERIX’s intention and
reason therefor, and providing DUKE with reasonable opportunity to assume responsibility for prosecution and maintenance of the patents. 

  
 - 5 -

 7.02 - MERIX shall be responsible for and pay all costs and expenses incurred during the
term of this Agreement, for the preparation, filing, prosecution, issuance and maintenance of the Patent Rights. MERIX shall not allow Patent Rights to become abandoned due to nonpayment of fees without first affording DUKE the opportunity to assume
responsibility for further costs and expenses incurred relating to said Patent Rights. 
 7.03 - In the event that DUKE assumes
responsibility for prosecution and maintenance of the Patent Rights pursuant to Section 7.01 or 7.02 above, MERIX shall provide reasonable technical assistance to DUKE in the further prosecution of the Patent Rights. 

7.04 - In the event that this Agreement is terminated pursuant to Article 11 herein, the sole responsibility for applying for, seeking
prompt issuance of, and maintaining the Patent Rights shall revert to the DUKE, and DUKE shall pay expenses subsequently incurred for the preparation, filing, prosecution, issuance and maintenance of the Patent Rights. In the event that
responsibility for patent prosecution reverts to DUKE as specified in this section 7.04, MERIX shall, at its own expense, transfer all pertinent documents and materials related to the PATENT RIGHTS to DUKE in a timely manner. 

ARTICLE 8 - INFRINGEMENT BY THIRD PARTIES 
 8.01 - Upon learning of the infringement of PATENT RIGHTS by a third party, the party learning of such infringement shall promptly inform the other party in writing of that fact along with any evidence
available pertaining to the infringement. MERIX may at its own expense take whatever steps are necessary to stop the infringement and recover damages. In such case, MERIX will keep DUKE informed of the steps taken and the progress of any legal
actions taken. MERIX will pay to DUKE royalties pursuant to Article 3.01 on any such damages recovered as consideration for lost sales of LICENSED PRODUCTS that are in excess of legal expenses incurred by MERIX in enforcing its PATENT RIGHTS. If
MERIX does not undertake, within [**] days of notice, to enforce the PATENT RIGHTS against the infringing party, DUKE shall have the right, at its own expense to take whatever steps are necessary to stop the infringement and recover damages, and
shall be entitled to retain damages so recovered (after reimbursing MERIX for any of its expenses in cooperating with DUKE in prosecuting such infringement). 
 ARTICLE 9 - GOVERNMENT CLEARANCE AND EXPORT 
 9.01 - LICENSEE agrees to use
its best efforts to have the LICENSED PRODUCTS cleared for marketing and sale in those countries in which LICENSEE intends to sell LICENSED PRODUCTS by the responsible government agencies requiring such clearance. Where such clearance requires
payment of taxes or fees, LICENSEE shall maintain full responsibility for that payment, which shall not be creditable against any other amounts due under this AGREEMENT. To accomplish said clearances at the earliest possible date, MERIX agrees to
file, according to the usual practice of MERIX, any necessary data with said government agencies. 

  
 - 6 -

 9.02 - This AGREEMENT is subject to all of the United States laws and regulations
controlling the export of technical data, computer software, laboratory prototypes and other commodities and technology. 

ARTICLE 10 - PUBLICATION 
 10.01 - MERIX agrees that the right of publication of the              INVENTION and information in related PATENT RIGHTS shall reside in the
inventors and other staff of DUKE. DUKE shall use reasonable efforts to provide MERIX a review copy of such publications [**] days in advance of submission for publication or public disclosure, but such prior review by MERIX will be in no way
construed as a right to restrict such publication. Such review shall be granted solely so that DUKE and MERIX can perfect patent protection prior to public disclosure. MERIX shall also have the right to publish and/or
co-author any publication on the              INVENTION based upon data developed by MERIX. 

ARTICLE 11 - DURATION AND TERMINATION 
 11.01 - This AGREEMENT shall become effective upon the EFFECTIVE DATE, and unless sooner terminated in accordance with any of the provisions herein, shall remain in full force and effect for the longer
of: (i) the life of the last-to-expire of the patents included in the PATENT RIGHTS or any patents issued on KNOW-HOW; or
(ii)              (    ) years from the EFFECTIVE DATE hereof. Upon the expiration of this AGREEMENT, DUKE shall grant MERIX an exclusive, worldwide, fully paid
license, with the right to grant sub-licenses, under KNOW-HOW to make, have made, use, import, offer to sell, sell, offer to provide and provide LICENSED PRODUCTS.

 11.02 - MERIX may terminate this AGREEMENT by giving DUKE written notice at least three (3) months prior to such
termination, and thereupon terminate the manufacture, use or sale of LICENSED PRODUCTS. 
 11.03 - Either party may immediately
terminate this AGREEMENT for fraud, willful misconduct, or illegal conduct of the other party that materially adversely affects such party upon written notice of same to that other party. Except as provided above, if either party fails to fulfill
any of its material obligations under this AGREEMENT, the non-breaching party may terminate this AGREEMENT, upon written notice to the breaching party, as provided below. Such notice must contain a full
description of the event or occurrence constituting a breach of this AGREEMENT. The party receiving notice of the breach shall submit a plan to cure such breach to the non-defaulting party within [**] days of
receipt of such notice. The plan shall be subject to the reasonable acceptance, rejection or modification by the non-defaulting party within [**] days of receipt of the plan. The defaulting party shall have
the opportunity to cure that breach in accordance with the terms of the accepted plan. If the breach is not cured within that time, the termination will be effective as of the end of the cure period set forth in the accepted plan. A party’s
ability to cure a breach will apply only to the first two breaches properly noticed under the terms of this AGREEMENT, regardless of the nature of those breaches. Any subsequent breach by that party will entitle the other party to terminate this
AGREEMENT upon proper notice. 

  
 - 7 -

 11.04 - Upon the termination of this AGREEMENT, MERIX may notify DUKE of the amount of
LICENSED PRODUCTS MERIX then has on hand and MERIX shall then have a license to sell that amount of LICENSED PRODUCTS, but no more, provided MERIX shall pay the royalty thereon at the rate and at the time provided for herein. 

11.05 - If during the term of this Agreement, MERIX shall become bankrupt or insolvent or if the business of MERIX shall be placed in the
hands of a receiver or trustee, whether by the voluntary act of MERIX or otherwise, or if MERIX shall cease to exist as an active business, this Agreement shall immediately terminate as though with MERIX breach, and DUKE shall have all the remedies
and rights available to it for termination with cause; provided, however, that this provision shall not apply to a reorganization of MERIX under Chapter 11 of the United States Bankruptcy Code. 

ARTICLE 12 - LAW TO GOVERN 
 12.01 - This AGREEMENT shall be construed and enforced in accordance with the laws of the State of North Carolina. 
 ARTICLE 13 - NOTICES 
 13.01 - Notice hereunder shall be deemed sufficient
if personally delivered, if given by registered mail, postage prepaid, or by national overnight courier, charges prepaid, and in each instance addressed to the party to receive such notice at the address given below, or such other address as may
hereafter be designated by notice in writing. 
  

			
	DUKE	 	MERIX
		
	 Office of Science and Technology

Duke University
 Room 230, North
Building
 Box 90083
 Durham, NC
27708
	 	 P.O. Box 14509
 Research
Triangle Park, NC 27709
 ATTENTION: CEO

		
	 cc: Office of the University Counsel
 Duke University Medical Center
 DUMC Box 3024

2400 Pratt Street, Suite 4000
 Durham NC
27710
	 	 cc: Fred D. Hutchison, Esquire

Hutchison & Mason PLLC
 4011 Westchase
Blvd.
 Suite 400
 Raleigh NC
27607

  
 - 8 -

 13.02 - Information and transactions exchanged between the parties in relation to financial
consideration contemplated under this AGREEMENT, including but not limited to royalty reports and payments, shall be tendered to the following offices of each party respectively: 

 

			
	DUKE	 	MERIX
		
	 Office of Science and Technology

Duke University
 Room 230, North
Building
 Box 90083
 Durham, NC
27708
	 	 P.O. Box 14509
 Research
Triangle Park, NC 27709
 ATTENTION: CEO

		
	 cc: Office of the University Counsel
 Duke University Medical Center
 DUMC Box 3024

2400 Pratt Street, Suite 4000
 Durham NC
27710
	 	 cc: Fred D. Hutchison, Esquire

Hutchison & Mason PLLC
 4011 Westchase
Blvd.
 Suite 400
 Raleigh NC
27607

 ARTICLE 14 - ASSIGNMENT 
 14.01 - This AGREEMENT shall be binding upon and inure to the benefit of the respective successors and assigns of the parties hereto. However, MERIX may not assign its rights in this AGREEMENT without
approval by DUKE, such approval not to be unreasonably withheld; provided, however, that no such approval shall be required from DUKE if this AGREEMENT is assigned in connection with the sale of all or substantially all of the assets or stock of
MERIX, whether by merger, acquisition or otherwise. 
 ARTICLE 15 - INDEMNITY, INSURANCE, REPRESENTATIONS, STATUS

 15.01 - MERIX agrees to indemnify, hold harmless and defend DUKE, its officers, employees, and agents, against any and
all claims, suits, losses, damages, costs, fees, and expenses asserted by third parties, both government and non-government, resulting from or arising out of the exercise of the license granted under this
AGREEMENT. MERIX shall not be responsible for the negligence or intentional wrong doing of DUKE. 
 15.02 - MERIX shall maintain
in force at its sole cost and expense, with reputable insurance companies, general liability insurance and products liability insurance coverage in amounts customary for companies similarly situated in the same industry. DUKE shall have the right to
ascertain from time to time that such coverage exists, such right to be exercised in a reasonable manner. In lieu of said coverage, DUKE agrees to consider the existence of an adequate self-insurance program as an acceptable alternative. 

15.03 - NOTHING IN THIS AGREEMENT SHALL BE DEEMED TO BE A REPRESENTATION OR WARRANTY BY DUKE OF THE VALIDITY OF ANY OF THE PATENTS OR THE
ACCURACY, SAFETY, EFFICACY, OR USEFULNESS, FOR ANY PURPOSE, OF ANY PATENT RIGHTS. DUKE SHALL HAVE NO OBLIGATION, EXPRESS OR IMPLIED, TO SUPERVISE, MONITOR, REVIEW OR OTHERWISE ASSUME RESPONSIBILITY FOR THE PRODUCTION, MANUFACTURE, TESTING, MARKETING
OR SALE OF ANY LICENSED PRODUCT, AND DUKE SHALL HAVE NO LIABILITY WHATSOEVER TO MERIX OR ANY THIRD PARTIES FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE, OF ANY KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSESSED OR ASSERTED AGAINST, OR ANY
OTHER LIABILITY INCURRED BY OR IMPOSED UPON MERIX OR ANY OTHER PERSON OR ENTITY, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM: 
  

	 	a.	the production, use, or sale of any LICENSED PRODUCT; 

  
 - 9 -

	 	b.	the use of any PATENT RIGHTS by MERIX or its sublicensees; or 

  

	 	c.	any advertising or other promotional activities by MERIX with respect to any of the foregoing. 

15.04 - Neither party hereto is an agent of the other party for any purpose whatsoever. 

ARTICLE 16 - USE OF A PARTY’S NAME 
 16.01 - Neither party will, without the prior written consent of the other party: 
  

	 	a.	use in advertising, publicity or otherwise, any trade-name, personal name, trademark, trade device, service mark, symbol, or any abbreviation, contraction or simulation
thereof owned by the other party; or 

  

	 	b.	represent, either directly or indirectly, that any product or service of the other party is a product or service of the representing party or that it is made in
accordance with or utilizes the information or documents of the other party. 

 ARTICLE 17 - SEVERANCE, WAIVER
AND ALTERATION 
 17.01 - Each clause of this AGREEMENT is a distinct and severable clause and if any clause is deemed
illegal, void or unenforceable, the validity, legality or enforceability of any other clause or portion of this AGREEMENT will not be affected thereby. 
 17.02 - The failure of a party in any instance to insist upon the strict performance of the terms of this AGREEMENT will not be construed to be a waiver or relinquishment of any of the terms of this
AGREEMENT, either at the time of the party’s failure to insist upon strict performance or at any time in the future, and such terms will continue in full force and effect. 

17.03 - Any alteration, modification, or amendment to this AGREEMENT must be in writing and signed by both parties. 

ARTICLE 18 - CONFIDENTIALITY 
 18.01 - During the term of this AGREEMENT and for a period of [**] years following the expiration of termination of this AGREEMENT, DUKE and MERIX each agree to treat any confidential information
disclosed to it by the other party to this AGREEMENT with reasonable care and to avoid disclosure of such information to any other person, firm or corporation, except AFFILIATES, and either party shall be liable for unauthorized disclosure or
failure to exercise such reasonable care. Neither party shall have an obligation, with respect to confidential information disclosed to it, or any part thereof, which: 
  

	 	(a)	is already known to the party at the time of the disclosure; 

  
 - 10 -

	 	(b)	becomes publicly known without the wrongful act or breach of this AGREEMENT by the party; 

 

	 	(c)	is rightfully received by the party from a third party on a non-confidential basis; 

 

	 	(d)	is subsequently and independently developed by employees of the party who had no knowledge of the information, as verified by written records; or

  

	 	(e)	is approved for release by written authorization of the party disclosing the information. 

18.02 - DUKE and MERIX agree that any information to be treated as confidential information under this Article 18 must be disclosed in
writing or in another tangible medium and must be clearly marked “CONFIDENTIAL”. Information disclosed orally must be summarized and reduced to writing and communicated to the other party within [**] days, and the other party agrees that
such disclosed information shall be deemed confidential. 
 18.03 - Notwithstanding the foregoing, MERIX shall have the right to
use and disclose any Confidential Information related to the PATENT RIGHTS and KNOW-HOW to investors, prospective investors, employees and agents with a need to know, collaborators, prospective collaborators
and other third parties in the chain of manufacturing and distribution provided that MERIX obtains from such parties written confidentiality agreements the provisions of which are at least as strenuous as those provided in this Article 18. If a
party refuses to execute a written confidentiality agreement, MERIX may request from DUKE that such requirement be waived, such consent to waiver not to be unreasonably withheld by DUKE. 

ARTICLE 19 - TRANSFER OF MATERIALS 
 19.01 - Any transfer of materials between DUKE and MERIX in connection with this AGREEMENT shall be made under the terms of the Master Materials Transfer Agreement [MMTA], said MMTA being incorporated in
its entirety as Appendix B of the present AGREEMENT. 
 ARTICLE 20 - TITLES 

20.01 - All titles and article headings contained in this AGREEMENT are inserted only as a matter of convenience and reference. They do
not define, limit, extend or describe the scope of this AGREEMENT or the intent of any of its provisions. 

  
 - 11 -

 ARTICLE 21 - ENTIRE UNDERSTANDING 

21.01 - This AGREEMENT represents the entire understanding between the parties with respect to the subject matter hereof, and supersedes
all other agreements, express or implied, between the parties concerning the              INVENTION, and PATENT RIGHTS. 

  
 - 12 -

 IN WITNESS WHEREOF, the parties have caused these presents to be executed in
duplicate as of the date and year first above written. 
  

					
	SEAL	 	DUKE UNIVERSITY
			
		 	By:	 	  

		 		 	Robert Taber
		 		 	Director, Office of Science & Technology
			
		 	Date:	 	  

		
	SEAL	 	MERIX BIOSCIENCE, INC.
			
		 	By:	 	  

			
		 	Title:	 	  

			
		 	Date:	 	  

  
 - 13 -

 Appendix A 
 License Agreement for 1101 INVENTION and 1215 INVENTION 
 ROYALTY REPORT
for period ending              
 Duke File # 

 

																									
	 Country
	 	Product	 	Sales in
<Month>	 	Sales in
<Month>	 	Sales in
<Month>	 	Sales in
<Month>	 	Sales in
<Month>	 	Sales in
<Month>	 	TOTAL
GROSS
SALES1	 	Reductions
to Sales2	 	TOTAL
NET
SALES	 	%
Royalty
Due3	 	TOTAL
ROYALTY
DUE
													
	 SubTOTAL x Country
	 		 		 		 		 		 		 		 		 		 		 		 	
													
	 SubTOTAL x Country
	 		 		 		 		 		 		 		 		 		 		 		 	
													
	 GRAND TOTAL
	 		 		 		 		 		 		 		 		 		 		 		 	
												
		 		 		 		 		 		 	 Royalty Credits Taken
	 		 		 		 		 	
												
		 		 		 		 		 		 	 TOTAL Royalty Credits
	 		 		 		 		 	
													
	 ROYALTIES PAID
	 		 		 		 		 		 		 		 		 		 		 		 	

  

	1 	 Includes sales by Affiliates or by sublicensees of Merix. 

	2 	 Note that Reductions to Sales are limited by the definition of Net Sales as set forth in Section 1.01(f) of Article 1 of the License Agreement

	3 	 The Percentage of Royalty Due shall be decreased in accordance with Section 4.03 of Article 4 of the License Agreement

  
 - 1 -

 APPENDIX B: MASTER MATERIALS TRANSFER AGREEMENT 

MASTER MATERIAL TRANSFER AGREEMENT 
 between 
 DUKE UNIVERSITY 

Durham, NC 27710 

(“DUKE”) 

and 

MERIX BIOSCIENCE, INC. 
 Durham, NC 
 (“MERIX”) 

Pursuant to the License Agreement between the parties dated 10 January 2000 for the inventions described in the Duke University
Office of Technology file # 1101 and 1215 (the “LICENSE AGREEMENT”) and subject to the terms of the LICENSE AGREEMENT, this Master Material Transfer Agreement (“Agreement”) defines the terms by which either party hereto shall
have the right to request reasonable amounts of research materials from the other party which are reasonable, necessary, and useful to the purposes of the LICENSE AGREEMENT (“Original Materials”), such requests not to be unreasonably
denied. Hereinafter, the party providing its Original Materials shall be referred to as the “PROVIDING PARTY” and the party receiving the other party’s Original Materials shall be referred to as the “RECEIVING PARTY”. It is
understood and agreed that “PROVIDING PARTY” and “RECEIVING PARTY” shall include the Affiliates of MERIX or DUKE as defined below. 
 For the purposes of this Agreement, the following definitions shall be recognized by both parties: 
 Progeny: Unmodified descendant from the Original Materials, such as virus from virus, cell from cell, or organism from organism. 

Unmodified Derivatives: Substances created by the RECEIVING PARTY which constitute an important unmodified
functional sub-unit or expression product of the Original Materials, e.g., subclones of unmodified cell lines, purified or fractionated sub-sets of the Original
Materials such as novel plasmids or vectors, proteins expressed by DNA or RNA, or antibodies secreted by a hybridoma. 
 Material: Original Material plus Progeny and Unmodified Derivatives or any related biological material or associated know-how and data received by Receiving
Party from Providing Party. Material shall not include any Modifications (as defined below). 

Modifications: Substances created by the RECEIVING PARTY which contain/incorporate any form of the Material
(Original Materials, Progeny or Unmodified Derivatives). 

  
 - 1 -

 Affiliates: Any corporation or
non-corporate entity which controls, is controlled by, or is under common control with a party hereto. A corporation or non-corporate entity, as applicable, shall be
regarded as in control of another corporation if it owns or directly or indirectly controls at least fifty percent (50%) of the voting stock of the other corporation or if it possess, directly or indirectly, the power to direct or cause the
direction of the management and policies of such corporation or non-corporate entity, as applicable. 

Materials are to be provided under the following terms and conditions: 
  

	1)	Exchange of Original Materials shall be documented through the use of Material Transfer Record forms, samples of which are appended hereto as Exhibits I and II.
Materials are and shall remain the property of the PROVIDING PARTY. Subject to Section 8 of this Agreement, Materials shall be used by the RECEIVING PARTY solely for research and development purposes, including those purposes permitted in the
LICENSE AGREEMENT. The Materials shall be used at RECEIVING PARTY’s facilities only unless prior written consent to the transfer of the Materials has been obtained from the Providing Party. RECEIVING PARTY agrees not to transfer the Materials
or Modifications to anyone who does not work under its direct supervision at RECEIVING PARTY’s facilities without the prior written consent of PROVIDING PARTY. RECEIVING PARTY agrees to protect Confidential Information supplied by PROVIDING
PARTY regarding Materials in accordance with the confidentiality provisions set forth in the LICENSE AGREEMENT. 

  

	2)	PROVIDING PARTY does not claim ownership of substances and Modifications produced as a result of RECEIVING PARTY’s research with materials that are not included in
the definition of Materials above. Notwithstanding the foregoing and subject to Section 5 hereof, PROVIDING PARTY retains ownership of any form of the Materials contained in a Modification. 

 

	3)	DUKE shall be free to use the results of its research with the Materials for its own teaching, research, educational, clinical and publication purposes without the
payment of royalties or other fees to MERIX. Confidential Information shall be governed by the confidentiality provisions contained in the LICENSE AGREEMENT. Should RECEIVING PARTY wish to publish the results of its research from the Materials
provided by PROVIDING PARTY, RECEIVING PARTY shall submit in writing to PROVIDING PARTY, for its review and comment, a copy of any proposed publication resulting from the subject research with the Materials at least [**] days prior to the estimated
date of publication, and if no response is received from PROVIDING PARTY within [**] days of the date submitted to PROVIDING PARTY, it will be conclusively presumed that the publication may proceed without delay. RECEIVING PARTY shall acknowledge
PROVIDING PARTY as the source of the Materials in all publications containing any data or information about the Materials, unless PROVIDING PARTY indicated otherwise and subject to the confidentiality provisions set forth in the LICENSE AGREEMENT.
If PROVIDING PARTY determines that the proposed publication contains patentable subject matter or the disclosure of Confidential Information which requires protection, PROVIDING PARTY may require the delay of the publication for a period of time not
to exceed [**] days for the purpose of allowing the pursuit of such patent protection or the deletion of Confidential Information. In the case of joint publications, authorship shall be determined by normal academic standards, taking into account
the role and contribution of each investigator. 

  
 - 2 -

	4)	RECEIVING PARTY will inform PROVIDING PARTY, in confidence, of research results related to the Material by personal written communication or by providing PROVIDING
PARTY with a draft manuscript describing the results of such research. PROVIDING PARTY shall accept and maintain such results in confidence until published. 

 

	5)	Except as expressly provided in this Agreement or the LICENSE AGREEMENT, transfer of Materials conveys no rights to RECEIVING PARTY under any patent applications,
patents, trade secrets or other proprietary rights of PROVIDING PARTY except as provided in the LICENSE AGREEMENT. In particular, no rights are provided to RECEIVING PARTY for use of the Materials or Modifications for profit-making or commercial
purposes except as provided in the LICENSE AGREEMENT. If RECEIVING PARTY desires to use the Materials or Modifications for such commercial purposes, RECEIVING PARTY agrees that it must first negotiate a license or other appropriate agreement with
PROVIDING PARTY and third parties as may be required. However, to the extent that PROVIDING PARTY can legally do so, RECEIVING PARTY is hereby granted a non-exclusive, royalty-free license to use Material
included in Modifications for RECEIVING PARTY’s own internal noncommercial research purposes. RECEIVING PARTY shall not use PROVIDING PARTY’s Materials or Modifications in research that is subject to consulting or licensing obligations to
a third party, unless prior written permission is obtained from PROVIDING PARTY. PROVIDING PARTY shall be free, in its sole discretion, to distribute its Materials to others and to use its Materials for its own purposes to the full extent it may
legally do so. 

  

	6)	If RECEIVING PARTY’S research results in a discovery, an invention, a new use or a product (collectively referred to as “Materials Discovery”), based on,
containing, or relating to the Materials or Modifications received from PROVIDING PARTY, RECEIVING PARTY shall promptly and confidentially disclose the Materials Discovery to the PROVIDING PARTY as well as the role, if any, of RECEIVING PARTY, its
employees’ and/or agents in the creation of the Materials Discovery. Inventorship of any Materials Discovery shall be determined by patent law or by mutual agreement if the Materials Discovery is not patentable. Title to Materials Discoveries
shall reside with MERIX if MERIX personnel are the sole inventors, with DUKE if DUKE personnel are the sole inventors, and will be held jointly if both DUKE and MERIX personnel are inventors. To the extent that DUKE owns the rights of sole or joint
inventorship of any Materials Discovery, MERIX is hereby granted an option to acquire an exclusive, worldwide, royalty-bearing license as set forth in the LICENSE AGREEMENT. Notwithstanding the above, PROVIDING PARTY or joint owner of any Materials
Discovery shall be free to use any Materials Discovery for its own internal research purposes without the payment of royalties or other fees. 

  
 - 3 -

	7)	Any Materials delivered pursuant to this Agreement are understood to be experimental in nature, and PROVIDING PARTY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES
OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIALS OR MODIFCATIONS THEREOF WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR
OTHER PROPRIETARY RIGHTS. 

  

	8)	In no event shall PROVIDING PARTY be liable for any use by RECEIVING PARTY, its employees and/or agents of Materials or for any loss, claim, damage, or liability, of
any kind or nature, that may arise from or in connection with RECEIVING PARTY’s use, handling, storage, or disposal of the Materials or Modifications, except as such claims, demands, costs or judgment arise from PROVIDING PARTY’s
negligence or willful misconduct. Except to the extent prohibited by law, RECEIVING PARTY assumes responsibility for, and agrees to indemnify and hold harmless PROVIDING PARTY and PROVIDING PARTY’s trustees, directors, officers, agents, and
employees from and against any liability, loss or damage they may suffer as a result of any claims, demand, costs or judgments against them arising out of RECEIVING PARTY’s use, handling, storage or disposal of the Materials or Modifications,
except as such claims, demands, costs, or judgments may also arise from the indemnified party’s negligence or willful misconduct or from PROVIDING PARTY’s publication or distribution of any reports, data or other information relating to
said Material. 

  

	9)	Materials or Modification shall in no event be used in human beings (including for diagnostic purposes), and all research involving the Materials or Modifications
(including but not limited to research involving the use of animals and recombinant DNA) shall be conducted in accordance with all federal, state, local and other laws, regulations, and ordinances governing such research, including applicable NIH
guidelines, if used in the United States. 

  

	10)	This Agreement will become effective when signed by both parties and shall terminate upon the termination or expiration of the LICENSE AGREEMENT, unless extended by
written mutual agreement between MERIX and DUKE. Upon termination of this Agreement, RECEIVING PARTY will at the direction of PROVIDING PARTY immediately discontinue its use of PROVIDING PARTY’s Materials and will, upon direction of PROVIDING
PARTY, return or destroy such Materials promptly upon notice. RECEIVING PARTY will have the option of either destroying Materials and/or Modifications of PROVIDING PARTY’s Materials or remain bound by the terms of this Agreement as they apply
to such Materials and/or Modifications, as the case may be. Paragraphs 2, 3, 4, 5, 6, 7, 8, 10 and 11 shall survive termination of this Agreement. 

  

	11)	Neither party shall use the name of the other party in any advertising, publicity or otherwise without the written consent of the other party. 

  
 - 4 -

	12)	Neither party may assign this Agreement without the prior written consent of the other party; provided, however, that no such consent shall be required in connection
with the sale of all of substantially all the assets or capital stock of a party, whether by merger, sale of stock or assets or otherwise. This Agreement shall be governed by the laws of the State of North Carolina, without reference to its choice
of law provisions. The parties hereby submit to the jurisdiction of the courts of North Carolina in all matters concerning this Agreement. 

 AGREED: 
  

											
	DUKE:	 	MERIX:	 	
			
	Duke University	 	Merix Bioscience Inc.	 	
						
	By:	 	  
	 		 	By:	 	  
	 	
	Andrew E. Balber, Ph.D.	 		 	Name:	 	  
	 	
	Associate Director	 		 	Title:	 	  
	 	
	Office of Science & Technology	 		 		 		 	
			
	Date executed:                      	 	Date executed:                      	 	

  

  
 - 5 -

 EXHIBIT I 
 MATERIAL TRANSFER RECORD 
 Duke University 

Durham, NC 27710 

(“PROVIDING PARTY”) 
 to 
 MERIX BIOSCIENCE, Inc. 

Durham, NC 

(“RECEIVING PARTY”) 

The Original Materials described below are supplied by PROVIDING PARTY to RECEIVING PARTY subject to the terms and conditions of the LICENSE AGREEMENT
between Duke University and MERIX, Inc. dated 10 January 2000 for the inventions described in the Duke University Office of Technology Transfer file # 1101 and 1215 (the “LICENSE AGREEMENT”) and the Master Materials Transfer Agreement
dated                      between such parties. Duplicate originals of this form shall be executed and one fully executed form shall be given to the
Principal Investigator of PROVIDING PARTY and one to the Principal Investigator of RECEIVING PARTY. 
  

					
	Description of Original Materials:	 	  
	 	
	
	  

	
	  

 In signing below, PROVIDING PARTY’s Principal Investigator and the RECEIVING PARTY’s Principal Investigator
acknowledge that they understand and will abide by the terms and conditions of the LICENSE AGREEMENT and Master Materials Transfer Agreement pursuant to which the Original Materials are provided. 

AGREED: 
  

					
	PROVIDING PARTY	 		 	RECEIVING PARTY
			
	  
	 		 	  

	Principal Investigator	 		 	Principal Investigator
			
	  
	 		 	  

	Date Material(s) sent	 		 	Date Material(s) received

  
 - 6 -

 EXHIBIT II 
 MATERIAL TRANSFER RECORD 
 MERIX BIOSCIENCE, Inc. 

Durham, NC 

(“PROVIDING PARTY”) 
 to 
 Duke University 

Durham, NC 27710 

(“RECEIVING PARTY”) 

The Original Materials described below are supplied by PROVIDING PARTY to RECEIVING PARTY subject to the terms and conditions of the License Agreement
between Duke University and MERIX BIOSCIENCE, Inc. dated 10 January 2000 for the inventions described in the Duke University Office of Technology Transfer file # 1101 and 1215 (the “LICENSE AGREEMENT”) and the Master Materials
Transfer Agreement dated                      between such parties. Duplicate originals of this form shall be executed and one fully executed form
shall be given to the Principal Investigator of PROVIDING PARTY and one to the Principal Investigator of RECEIVING PARTY. 
  

					
	Description of Original Materials:	 	  
	 	
	
	  

	
	  

 In signing below, PROVIDING PARTY’S Principal Investigator and RECEIVING PARTY’S Principal Investigator
acknowledge that they understand and will abide by the terms and conditions of the LICENSE AGREEMENT and Master Materials Transfer Agreement pursuant to which the Original Materials are provided. 

AGREED: 
  

					
	PROVIDING PARTY	 		 	RECEIVING PARTY
			
	  
	 		 	  

	Principal Investigator	 		 	Principal Investigator
			
	  
	 		 	  

	Date Material(s) sent	 		 	Date Material(s) received

  
 - 7 -

 FIRST AMENDMENT TO 

EXCLUSIVE LICENSE AGREEMENT 
 THIS FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (the “First Amendment”) is made and dated as of July 28, 2003, by and between MERIX Bioscience, Inc., a Delaware corporation with
its principal place of business at 4233 Technology Drive, Durham, NC 27704 (“MERIX”), and Duke University, a North Carolina not-for-profit corporation
having its Office of Science and Technology offices located at the Grey Building, 2020 E. Main Street, Durham, NC 27705 (“DUKE”). 
 WHEREAS, MERIX and DUKE are parties to that certain Exclusive License Agreement dated January 10, 2000 whereby MERIX obtained certain rights in and to patents and
know-how described in DUKE’s Office of Science and Technology files #1215 (the “License Agreement”); and 
 WHEREAS, the parties hereto desire to modify the terms of the License Agreement. 

NOW, THEREFORE, in consideration of the mutual agreements contained herein, the adequacy and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows: 
 1. Defined Terms. Terms that are used herein with initial capital
letters and that are not otherwise defined shall have the meanings given to them in the License Agreement. 
 2. Article
2.02. Article 2.02 of the License Agreement is hereby amended by appending the following clause to the end of such article: 
 “, and DUKE agrees that all such sublicenses assigned to DUKE shall survive the termination or expiration of this AGREEMENT. DUKE further agrees that any sublicensee of MERIX shall have the right to
further sublicense the PATENT RIGHTS, subject to the terms of this AGREEMENT” 
 3. Article 7.04. The following new
Article 7.04 is incorporated into the License Agreement: 
 “7.04—MERIX shall have the right to
delegate some portion of its obligations under this Article 7 to its sublicensees, subject to providing timely notice to DUKE of its intention to do so and further subject to such sublicensee agreeing to assume such obligations. In the event that
this AGREEMENT is terminated, such rights and obligations previously assumed by such sublicensees shall survive.” 
 4.
Article 7.05. Exisitng Article 7.04 is re-numbered as Article 7.05, the reference in the article to section 7.04 is amended to be 7.05, and the following language is inserted at the beginning of the
first sentence of the article: 
 “Except as otherwise set forth in Section 7.04,” 

5. Article 8.01. Article 8.01 of the License Agreement is hereby amended by inserting the following language following the first
complete sentence of the article: 

 “MERIX shall have the first right to enforce any of the PATENT RIGHTS
against any third party against any infringement or alleged infringement thereof.” 
 6. Article 8.01. Article 8.01
of the License Agreement is hereby further amended by inserting the following language following the third complete sentence of the article: 
 “MERIX shall have the right, as reasonably required, to name DUKE as a necessary party, or to bring suit in DUKE’s name, in any legal actions taken by MERIX hereunder but only to protect
MERIX’ interest in the licensed technology.” 
 7. Article 8.02. The following new Article 8.02 is incorporated
into the License Agreement: 
 “8.02—MERIX shall have the right to delegate its obligations with
respect to some portion of the PATENT RIGHTS under this Article 8 to its sublicensees, subject to providing timely notice to DUKE of its intention to do so and further subject to such sublicensee agreeing to assume such obligations. In the event
that this AGREEMENT is terminated, such rights and obligations previously assumed by such sublicensees shall survive.” 

8. Effect of First Amendment. The provisions of the License Agreement are amended and modified by the provisions of this First
Amendment. If any provisions of the License Agreement are materially different from or inconsistent with any of the provisions of this First Amendment, the provisions of this First Amendment shall control, and the provisions of the License Agreement
shall, to the extent of such difference or inconsistency, be deemed to be amended and modified. 
 9. Single Agreement.
This First Amendment and the License Agreement, as amended and modified by the provisions of this First Amendment, shall constitute and be construed as a single agreement. 
 10. Governing Law. This First Amendment shall be governed by and construed in accordance with the laws of the State of North Carolina. 

IN WITNESS WHEREOF, the parties hereto have duly executed this First Amendment as of the date first written above. 

 

			
	DUKE UNIVERSITY
		
	 By:
	 	/s/ Robert L. Taber
		 	  

		 	 Robert L. Taber, Ph.D.

Vice Chancellor and Director
 Office of Science
& Technology

		 	
	
	MERIX BIOSCIENCE, INC.
		 	
	By:	 	/s/ Timothy W. Trost
		 	  

		 	 Name:  Timothy W. Trost

Title:    Vice President & CFO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]